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Despite the success of antiretroviral therapy (ART), eradication of HIV-1
from brain reservoirs remains elusive. HIV-1 brain reservoirs include perivascular
macrophages that are behind the blood-brain barrier and difficult to access by
ART. Macrophages express transcription factor FOXO3a and the TNF
superfamily cytokine TRAIL, which are known to target HIV-1-infected
macrophages for viral suppression. ONC201 is a novel and potent FOXO3a
activator capable of inducing TRAIL. It can cross the blood-brain barrier, and has
shown an antitumor effect in clinical trials. We hypothesized that activation of
FOXO3a/TRAIL by ONC201 will reduce the size of HIV-1 brain reservoirs. Using
primary human monocyte-derived macrophages, we demonstrated that ONC201
dose-dependently decreased HIV-1 replication levels as determined by HIV-1
reverse transcriptase activity assay and Western blots for p24. Consistent with
data on HIV-1 replication, ONC201 also reduced integrated HIV-1 DNA in
infected macrophages in two-step Alu-based nested PCR. In addition, the
antiviral effect of ONC201 is applicable to different natural HIV strains and to
lymphocytes, microglia and latently infected cell line. A combination of ONC201
and AZT achieved a longer and synergistic viral suppression in HIV-1 infected

macrophages. The anti-HIV-1 effect of ONC201 was further validated in vivo in
NOD/scid-IL-2Rcnull

mice.

After

intracranial

injection

of

HIV-1-infected

macrophages into the basal ganglia, we treated the mice daily with ONC201
through intraperitoneal injection for 6 days. ONC201 significantly decreased p24
levels in both the macrophages and the brain tissues, suggesting that ONC201
suppresses HIV-1 in vivo. As for the mechanisms, ONC201 treatment activated
FOXO3a and induced TRAIL expression in macrophages while blocking TRAIL
or knockdown of FOXO3a with siRNA reversed ONC201-mediated HIV-1
suppression, suggesting that ONC201 inhibits HIV-1 through FOXO3a and
TRAIL. Furthermore, the antiviral effect of ONC201 is associated with apoptosis
and autophagy. Based on these in vitro and in vivo studies, ONC201 can be a
promising drug candidate to combat persistent HIV-1 infection in the brain
reservoirs.
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CHAPTER 1
Introduction
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1.1 Macrophage and microglia in HAND
Despite the success of antiretroviral therapy (ART), up to 70% of HIVinfected people are still suffering from neurocognitive and motor dysfunctions
collectively known as HIV-associated neurocognitive disorders (HAND) (1). The
high prevalence of HAND can be attributed to the long lifespan of HIV-infected
patients (2), the drug resistance of newly-mutated strains (3, 4), the low
penetration of the ART drugs on the blood-brain barrier (BBB) (5) and persistent
viral production from reservoir cells (6, 7). Notably, in the central nervous system
(CNS), only certain types of cells, macrophage and microglia are regarded as
reservoir cells for HIV-1. Macrophage and microglia can be preferentially
infected by M-tropic HIV strains, which are predominant for virus transmission in
vivo (8-11). The infected macrophages and microglia are exploited by HIV-1 to
spread virus to circulation and other organs for further infecting CD4+ T cells (12,
13). They also secrete a variety of proinflammatory cytokines, affecting the
nearby microenvironment and causing neuroinflammation (14). However, their
most unique role in CNS is serving as viral reservoirs. Compared with other
susceptible cells, macrophage and microglia have low turnover rates and are
particularly more resistant to the cytopathic effect of HIV-1 (15, 16). These
characteristics allow macrophage and microglia to keep integrated HIV-1 DNA
for month, which could be one of the mechanism of latency in this cells (17).
Latency, aside from low penetration of ART drugs on BBB, is another major
mechanism for the persistence of HIV-1 reservoirs in CNS. Infected cells that do
not produce infectious virions out of cells are viewed as in a state of latency.
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However, once stimulated by certain factors, they can start producing infectious
virions again. Whether there is “real” latency in macrophages and microglia is
still controversial because only very few macrophages (0.05%) are infected in
lymph nodes of HIV patients under HAART and their isolation and
characterization for HIV latency is difficult (18). Nevertheless, latency at least
can be established in MDMs in vitro (19). Generally, there are two types of
latency: pre-integration latency and post-integration latency (20). Pre-integration
latency may be due to low reverse transcription efficiency and inhibition of
nuclear transport of the pre-integration complex (20, 21); while post-integration
latency may be due to epigenetic gene silencing (22), transcription gene
silencing and post transcriptional gene silencing (23-25). Although new
generation of ART drugs are under development for better penetration in CNS,
they can only target HIV virions for preventing new infection on susceptible cells.
However, HIV-1 enters the CNS in the first week of acute infection and already
establishes latency there before ART drugs reach (18, 26), which makes a
complete eradication of HIV in CNS reservoirs by ART impossible without help
of other strategies.
Two entirely opposite strategies have been proposed to assist ART in
managing the HIV-1 reservoir cells in latency. “Block and lock” strategy aims to
block the reactivation of latent viruses and permanently lock them in the state of
latency (27), while “flushing out” strategy aims to reactivate the latent virus in
latently infected cells, leaving those cells under attacks from host immune
system and ART drugs (20). The drugs that promote HIV-1 reactivation are
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called latency-reversing agent (LRA) (28, 29). Histone deacetylases (HDACs)
participate in restraining HIV-1 proviral DNA expression (30), thus serving as a
potential target for “flushing out” strategy. However, HDAC inhibitors such as
vorinostat did not decease the HIV-1 proviral DNA in CD4+ T cells and rectal
tissues, even after successfully reactivating HIV-1 from latency in patients under
ART treatment (31, 32). An adapted or alternative strategy for “flushing out” is
“prime, shock and kill”, which aims to sensitize the latently-infected reservoir
cells for apoptosis and death (33). So far only an antifungal drug, ciclopirox, and
an iron chelator, deferiprone, have shown an antiviral effect through inducing
apoptosis in HIV-1 infected H9 cells and peripheral blood monocytes (34).
However, there was no evidence demonstrating their safety inside the body.
Notably, the agents that induce apoptosis in tumor cells may have the similar
effect in infected reservoir cells. These apoptosis inducing agents include Bcl2
inhibitors (35), survivin inhibitors (36) and PI3K/AKT inhibitors (37). Further
investigations on these agents in the process of apoptosis within virally-infected
cells are warranted.
In the development of new drugs that target HIV-1 infected reservoir cells
for apoptosis, it is necessary to understand the mechanisms underlying the HIV1 induced apoptosis in the infected cells during HIV-1 pathogenesis. One of
mechanisms for host immune system to clear virally-infected cells is through the
induction of apoptosis. In addition, cytopathic effect of virus also causes the
death of infected cells though apoptosis. For macrophages, considerable
apoptosis has been found during Ebola virus infection, which is part of Ebola
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pathogenesis (38). However, whether HIV-1 induces apoptosis in macrophages
has been controversial. Noursadeghi et al. believed “no direct cytopathic effect
of HIV infection in monocyte-derived macrophages (MDM) (39), as shown by an
extensive body of literature (40)”. They also observed no induced apoptosis or
necrosis in MDM after establishment of uniform infection of HIV-1BaL (40). On
the other hand, Cui et al. observed significant apoptosis and cell death in MDM
in vitro after HIV-1 infection for 5-7 days, indicating macrophages still undergo
apoptosis after the long-time “no uniform” HIV-1 infection (41). This controversy
highlights the mixed and complicated process of apoptosis potentially induced
by HIV-1 in macrophages. During HIV-1 infection, the virus-encoded proteins
regulate both pro- and anti-apoptotic factors in host cells, leading to a modified
destiny of the infected cells in the purpose of survival and proliferation (42). As a
result, those apoptosis-resistant macrophages and microglia form HIV-1
reservoirs in the CNS, which is the major obstacle for the current ART that aims
to eradicate HIV-1 from CNS.

1.2 TRAIL
From the limited knowledge of HIV-1 induced apoptosis in infected
macrophage and microglia, TRAIL plays a critical role in this process. TRAIL,
short for TNF-related apoptosis-inducing ligand, is a type II integral membrane
protein. As a member of the TNF superfamily, TRAIL is structurally and
functionally related to FAS ligand (43, 44). TRAIL exists in two forms: surfacebound one on the cell membrane and soluble one secreted to the extracellular
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space (45). There are five receptors for TRAIL: TRAIL receptor one (R1) and
receptor two (R2) have death domains (46-48); TRAIL-R3 and TRAIL-R4 have
similar structures but do not possess these domains (49, 50); the fifth TRAIL
receptor is soluble and also called osteoprotegerin (51). Thus, in order to induce
apoptosis, TRAIL need to bind to TRAIL-R1 or -R2, while TRAIL-R3 and -R4 act
as decoy receptors to block this effect. TRAIL can homo-oligomerize with its
death receptors to recruit the initiators of apoptosis cascade, such as
procaspase-8.
Under physiological conditions, TRAIL is actively transcribed in many
human tissues except that its expression is absent in brain tissue. Neurons (52),
astrocytes (53-55), macrophage and microglia (56) express TRAIL at minimal
levels in the normal conditions. However, all types of brain cells express one or
a combination of TRAIL receptors (57, 58). Thus, cells in the CNS are sensitive
to TRAIL, as massive and non-selective cell death can be induced by TRAIL
treatment on a brain slice culture (57). Under pathological conditions such as
HIV-1 infection, tat protein and immune activation by interferon-γ (IFN-γ) and
lipopolysaccharide (LPS), TRAIL expression is substantially upregulated in
macrophage and microglia (56, 59, 60). Meantime, these conditions may
undermine the high resistance of macrophage and microglia to TRAIL-induced
apoptosis (61).
The role of TRAIL in HIV pathogenesis has been perplexing. On the one
hand, treating HIV-1 infected CD4+ T cells and macrophage with high levels of
TRAIL agonists preferentially killed HIV-1 infected cells and shrank the size of
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viral reservoir ex vivo (62). On the other hand, TRAIL is highly expressed in cells
from HIV-1 infected patients (63), and the levels of TRAIL in plasma are higher
in HIV-1 infected patients compared with heathy individuals while ART
decreases the levels of those soluble TRAILs (64). However, infected cells still
cannot be eradicated in such natural conditions. These results demonstrate that
HIV-1 infected cells may survive the elevated level of TRAIL in infected patients
but still could not tolerate supraphysiologic levels of TRAIL brought by
pharmacological intervention. This finding encourages researchers to continue
searching for new TRAIL inducers while investigating the mechanisms by which
TRAIL induce apoptosis in HIV-1 infected cells.
The signaling pathway of TRAIL in HIV-1 infected macrophage and
microglia is partially elucidated. Generally, HIV-1 infection inhibits Akt
phosphorylation while inducing the expression of TRAIL and its death receptor,
which subseqently leads to cell apoptosis. Specifically, first, one of the
mechanisms for HIV-1 infection to induce TRAIL expression has been reported.
Step 1: HIV-1 infection induces the expression of IRF-1 and IRF-7 and activates
STAT1; Step2: IRF-1 and IRF-7 promote Type I IFNs production and
subsequent STAT1 activation; Step3: Type I IFNs and STAT1 activation further
enhance the expression of IRF-1 and IRF-7; Step4: accumulated STAT1 and
IFNs induce the transcription of TRAIL; together, a positive feedback loop is
formed to upregulate TRAIL expression (65). Second, the mechanism for TRAIL
to induce apoptosis in HIV-1 infected macrophages has been investigated. HIV1 infection reduces Akt-1 phosphorylation in macrophages while TRAIL-
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mediated apoptosis is dependent on the inhibition of Akt-1 phosphorylation (66).
Third, in vitro HIV-1 infection was associated with increased levels of TRAIL-R1,
which might be one of reasons that TRAIL preferentially induces cell death of
HIV-1 infected macrophages without hurting uninfected macrophages (62).

1.3 FOXO3a
TRAIL ligand is under transcriptional control of a transcription factor,
FOXO3a, which is a member of Forkhead Class O (FOXO) family. This family
has four members: FOXO1, FOXO3 (also called FOXO3a), FOXO4 and FOXO6.
They all share a conserved DNA-binding domain (the “Forkhead box”) and are
characteristically regulated by the insulin/PI3K/Akt signaling pathway. By
transcribing multi-category genes, FOXO family members play critical roles in a
variety of cellular activities, including cell death (Bim-1, FasL), reactive oxygen
species detoxification (Catalase, MnSOD), DNA repair (GADD45, DDB1), cell
cycle arrest (p27, p130, GADD45, Cyclin G2), glucose metabolism (G6Pase,
PEPCK) and energy homeostasis (AgRP, NPY) (67).
The regulation of FOXO3a is mainly responsive to environmental conditions.
Insulin or growth factors trigger the PI3K/Akt activation to phosphorylate
FOXO3a at three conserved residues, prompting the translocation of FOXO3a
from the nucleus to the cytoplasm and therefore reducing FOXO3a-mediated
transcription. Under oxidative stress, other protein kinases such as JNK and
Mst1 phosphorylate FOXO3a at other sites, resulting in the import of FOXO3a
from cytoplasm to the nucleus and therefore inducing FOXO3a-dependent
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transcription (67). In addition, FOXO3a can be regulated through acetylation,
deacetylation, monoubiquitination, polyubiquitination under other environmental
conditions including nutrient deprivation and hypoxia (67-69). FOXO3a functions
as a coordinator of cell cycle arrest, stress resistance and apoptosis to respond
to the volatile environment, as it regulates both pro-apoptotic and anti-apoptotic
genes at the same time (70).
In the immune system, FOXO3a is the predominant FOXO member
expressed in peripheral lymphoid organs and mediates lymphoid homeostasis
(71). FOXO3a regulates helper T cell activation and tolerance by inhibiting NFκB activity, and FOXO3a deficiency causes spontaneous lymphoproliferation
with inflammation of several organs in the absence of apparent apoptotic
defects (71-73). FOXO3a mediates the protective effect of glucocorticoidinduced leucine zipper (GILZ) on T lymphocytes from IL-2 withdrawal-induced
apoptosis (74). Convergence of TCR and cytokine signaling inactivates
FOXO3a and drives the survival of CD4+ central memory T cells (75).
Inactivation of FOXO3a is also required for optimal B-cell proliferation (76).
However, the knowledge of the exact function and detailed regulation of
FOXO3a in macrophage and microglia is still limited. For HIV-1 infected
macrophages, HIV-1 infection inhibits Akt-1 to activate FOXO3a, thereby
inducing apoptosis and cell death (41). Thus, FOXO3a may also act as a key
factor regulating the apoptosis of macrophage.

1.4 ONC201

10
ONC201, also known as TIC10, is a small molecule compound that has a
chemical nomenclature of 7-benzyl-4-(2-methylbenzyl)-1,2,6,7,8,9-Hexahydroimidazo [1,2-a]pyrido [3,4-e] pyrimidin- 5(1H)-one. It is the founding member of
the imipridone class of compounds that share a unique imidazo pharmacophore
(Fig. 1.1A). It was first identified as a candidate anti-cancer lead compound for
the induction of TRAIL in a colorectal cancer cell line (77, 78). The specific antitumor activity of ONC201 has been demonstrated in over 15 solid tumors and
hematological malignancies either in single agent treatment or in combination
regimens in preclinical models (see review at (79)).
Being selected as the lead compound for clinical application, ONC201 has
several advantages. ONC201 is orally active and can cross BBB. In the
experiment on rodents, it penetrated intact BBB and accumulated in brain with
higher concentrations than in plasma (78). So far, 14 clinical trials are testing
ONC201 on brain tumors (Clinicaltrials.gov). ONC201 also shows outstanding
safety profile both in vitro and in vivo (80). It does not induce apoptosis in
normal cells possibly due to blunted ISR activation and the absence of death
receptor 5 (DR5) induction (78). In the first human Phase I clinical trial on
ONC201, a dose of 625 mg administered orally every three weeks was welltolerated (81).
ONC201 was discovered by a “phenotypic cell-based screen, rather than a
target structure-based approach” (79). Thus, its direct binding target has not
been confirmed yet. A novel target prediction algorithm as a Bayesian machinelearning approach analyzed millions of data points and predicted that ONC201
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should have a highly specific affinity with dopamine receptor D2 (DRD2)
(unpublished data, (79)). This result has been supported by both in vitro and
clinical data. Experimental GPCR profiling and reporter assays showed that
ONC201 antagonized the D2-like, but not D1-like, subfamily of dopamine
receptors (79). In Phase I clinical trial of ONC201, pharmacodynamic assays
demonstrated induction of prolactin as a serum biomarker of DRD2 antagonism
in human subjects receiving ONC201 treatment (81). However, DRD2 has not
been placed in the signaling pathway of ONC201 yet, due to lack of data linking
it to induction of TRAIL.
In cancer cells, ONC201 induces the transcription of TRAIL and the
following

apoptosis

through

two

pathways.

The

first

pathway

is

Akt/ERK/FOXO3a/TRAIL/DR5 signaling axis. ONC201 indirectly inactivate prosurvival kinases Akt and ERK, which dephosphorylate transcription factor
FOXO3a at Ser253 and Ser294, respectively. The unphosphorylated FOXO3a
leaves cytoplasmic 14-3-3 proteins which once sequester it in cytoplasm, and
then translocates to nucleus where it binds to the TRAIL promoter and induces
the transcription of TRAIL. Soluble TRAIL and surface-bound TRAIL could bind
to DR5 on the membrane of TRAIL-producing cells or nearby cells for induction
of apoptosis. The second pathway is ER stress/ISR/eIF2a/ATF4/CHOP/DR5
and TRB3 signaling axis. ONC201 induces ER stress. Then the integrated
stress response (ISR) increases phosphorylation of eukaryotic initiation factor 2
(eIF2a), which promotes translation of ATF4. ATF4 is the transcription factor for
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CHOP and TRB3. CHOP targets DR5 to induce apoptosis while TRB3 is
necessary for Akt inactivation, which is the bridge between two pathways (79).
ONC201 has an isomer which is the "inactive version" of ONC201 (Fig.
1.1B). ONC201 isomer was introduced to the research community since it was
structurally wrong-assigned as the bioactive ONC201 during early stage
development of ONC201 (82). ONC201 isomer was found to be inactive, which
did not reduce the viability of cancer cells (82). It is often used as a reference
compound to compare with ONC201.

1.5 conclusion
Macrophages and microglia are the HIV-1 reservoir cells in the CNS,
contributing to the pathogenesis of HAND. Current ART is not able to eradicate
HIV-1 from these latently infected long-lived cells to terminate HIV-1 infection.
One mainstream strategy to manage reservoir cells is “prime, shock and kill”.
However, the requirement of selective killing infected cells without damaging
norm tissues prompts us to understand the mechanism of HIV-1-induced
apoptosis in macrophages and microglia. So far it has been reported that HIV-1
induces apoptosis in macrophages by activating transcription factor FOXO3a
and promoting the expression of proapoptotic TRAIL. Thus, FOXO3a-TRAIL
pathway may serve as a drug target to clear the HIV-1 infected macrophages
and microglia (Fig. 1.2).
Among all the TRAIL-based drugs, ONC201 as a small molecule compound
shows high performance on safety profile, therapeutic index, biodistribution and
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stability. It is orally active and can cross BBB, allowing it to reach a high
therapeutic concentration around the niche of reservoir cells in the CNS.
Although its direct binding target is not confirmed, ONC201 has been shown to
indirectly activate FOXO3a and induce the expression of TRAIL. ONC201 has
been tested in Phase I and Phase II in-human clinical trials as an antitumor drug
and have shown a preferential apoptosis-inducing effect on tumor cells with
minimal cytotoxicity on normal cells. However, it has never been studied in the
field of infectious disease. Further exploring the effect of ONC201 on HIV-1
infected reservoir cells may endow this drug with a new application in clinics.

14
1.6 Figures
Figure 1.1 Molecular structure of ONC201 and its inactive isomer.
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Figure 1.2 Overview of the proposed drug targets (FOXO3a and TRAIL)
of ONC201 in HIV-1 CNS reservoirs.
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CHAPTER 2
ONC201 Inhibits HIV-1 Infection in vitro and in vivo.
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2.1 Abstract
HIV-1 continues to form reservoirs in the lymph system, gut and central
nervous system, representing a significant challenge for viral eradication.
FOXO3a, a transcription factor critical for immune homeostasis, is known to
inhibit latent HIV-1 reservoirs. Recent drug development has provided ONC201
as the first potent and stable small molecule FOXO3a activator capable of
crossing blood-brain barrier. We hypothesize that targeting FOXO3a through
ONC201 will inhibit HIV-1 in its reservoir cell types. Human primary microglia,
monocyte-derived macrophages and peripheral lymphocytes were infected with
HIV-1ADA, HIV Clade B or HIV Clade C in vitro. The toxicity of ONC201 was
determined by MTS cell viability assay. HIV-1 replication levels were measured
by HIV-1 reverse transcriptase activity assay, ELISA and Western blots for p24,
and RT-PCR for HIV-1 gag. HIV-1 integration was determined by two-step Alubased nested PCR. We found even at the highest soluble concentration,
ONC201 did not change the cell viability of macrophages and lymphocytes,
indicating ONC201 is safe for uninfected cells. ONC201, but not its inactive
isomer, potently inhibited HIV-1 replication and reduced integrated HIV-1 DNA in
infected cells in a dose-dependent manner, suggesting that the antiviral activity
is specific to ONC201. For in vivo study, HIV-1-infected macrophages were
intracranially injected into the basal ganglia of NOD/scid-IL-2Rcnull (NSG) mice.
Daily intraperitoneal injection of ONC201 for 6 days significantly decreased p24
levels in macrophages, suggesting that ONC201 suppresses HIV-1 in vivo. In
addition, to determine whether ONC201 synergizes with current anti-HIV-1
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treatment, we treated macrophages with ONC201 along with reverse
transcriptase inhibitor azidothymidine (AZT). Addition of ONC201 increased the
potency of AZT and achieved longer viral suppression during viral rebound.
Therefore, ONC201 can be a promising drug candidate to combat persistent
and latent HIV-1 infection in the current cART era.

19
2.2 Introduction
HIV continues to be a major global public health issue affecting more than
1.1 million people in the USA and 36.7 million people worldwide (83, 84).
Although application of antiretroviral therapy (ART) dramatically reduces the rate
of HIV-1 replication in infected patients, it is not able to eradicate HIV-1 from
cellular reservoirs in the lymphatic system, gut, and central nervous system
(CNS). Although many types of cells can be infected by HIV-1, cells that form
HIV reservoirs are typically long-lived, including memory CD4+ T cells (85), brain
perivascular macrophages, and microglia (86). In the CNS, macrophages and
microglia are the main cell types that can be productively infected by HIV-1. The
eradication of HIV reservoirs in the CNS is particularly challenging. Substantial
numbers of patients are still affected by HIV-1 associated neurocognitive
disorders (HAND) after apparently successful ART. Furthermore, many ART
drugs are not able to cross the blood-brain barrier (BBB) and reach therapeutic
concentrations within the CNS reservoirs. These long-lived HIV-1 reservoirs can
produce replication-competent HIV-1, which may spread to other tissues and
fuel the emergence of drug-resistant viral strains. Thus, strategies targeting
these CNS reservoir cells for HIV-1 eradication are urgently needed.
Vulnerabilities of HIV-1-infected brain macrophages and microglia include
the FOXO3a pathway and its transcriptional target TRAIL. FOXO3a is a
conserved transcription factor downstream of PI3K/Akt-1 pathway (87, 88). In
the absence of environmental signals or growth factors, FOXO3a is in an
unphosphorylated state and remains transcriptionally active. Growth factors
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activate the PI3K/Akt-1 signaling pathway, phosphorylating FOXO3a and
abrogating its transcriptional activity (89). FOXO3a is predominantly expressed
in peripheral lymphoid organs but the specific immunomodulatory role of
FOXO3a remains largely undefined (71). In memory CD4+ T cells under HIV-1
infection, multiple signals activate IκB kinase, which phosphorylates FOXO3a,
decreasing its ability to induce expression of various pro-apoptotic genes (90).
Our previous publications have demonstrated that FOXO3a targets HIV-1infected macrophages for apoptosis (41). Furthermore, we have determined that
FOXO3a is phosphorylated (inactive) during neuroinflammation and expression
of FOXO3a inhibits reactive astrogliosis in a neuroinflammatory mouse model
(91). Intriguingly, the transcriptional targets of FOXO3a include TRAIL, which is
a member of the TNF superfamily and is also known as TNF Superfamily
Member 10 (43, 44). TRAIL interacts with at least five unique receptors. TRAIL
receptor 1 (R1) and receptor 2 (R2) have death domains and induce cellular
apoptosis following ligand binding (46-48). TRAIL-R3, TRAIL-R4, and the fifth
receptor named osteoprotegerin do not possess death domains and instead act
as decoy receptors (49-51). Originally thought to target only tumor cells (43, 44),
TRAIL has been shown to reduce viral burden in HIV-1-infected macrophage
and resting memory CD4+ T cells (66, 92). While its receptors are expressed in
macrophage and microglia, TRAIL is expressed in much lower levels in the CNS
compared with the lymphoid tissues (58, 65, 93, 94). The deficiency of FOXO3a
signaling during HIV-1 infection and lack of TRAIL expression in the CNS may
inadvertently facilitate the forming of HIV-1 brain reservoirs. Therefore, targeting
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the FOXO3a-TRAIL pathway is a novel strategy to combat HIV reservoirs within
the CNS.
Targeting FOXO3a-TRAIL pathway has been difficult due to a lack of drug
candidates. However, recent drug development provides ONC201 as a potent
and stable small molecule that can activate FOXO3a and transcriptionally
induce TRAIL expression (77, 78, 95). ONC201 is orally active and can cross
the BBB (78). It has shown an efficacious antitumor effect and is currently being
tested in clinical trials as a promising anticancer agent (79). ONC201 also has
an inactive isomer which is naturally the optimal control to compare with
ONC201 in the research. In this study, we have investigated the anti-HIV-1
activity of ONC201. We demonstrate that ONC201 inhibits the HIV-1 infection
both in vitro in monocyte-derived macrophages and in vivo in NOD/scid-IL2Rcnull (NSG) mouse brains engrafted with HIV-1-infected macrophages. This
newly found activity of ONC201 suggests that it can serve as a drug candidate
to combat persistent HIV-1 infection in the CNS.
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2.3 Materials and Methods
Ethics statement and mice
Primary

monocyte-derived

macrophages

(MDM),

peripheral

blood

lymphocytes (PBL) and microglia were used in full compliance with the
University of Nebraska Medical Center and National Institutes of Health ethical
guidelines, with the Institutional Review Board (IRB) #: 162-93-FB. For animal
experiments, all mice were housed in the Comparative Medicine Animal
Facilities at the University of Nebraska Medical Center. All procedures were
conducted in accordance with the protocol (15-040-06) approved by the
Institutional Animal Care and Use Committee at the University of Nebraska
Medical Center. Fourteen four-week old male NOD.Cg-PrkdcscidIl 2rgtm1Wjl/SzJ
mice were purchased from Jackson Laboratories and HIV-1-infected human
MDM (5 105 cells, 3 l) were injected intracranially (IC) to the basal ganglion of
the mice. The coordinates for inoculation is: 0.5 mm posterior to bregma, 3.5
mm lateral and a depth of 3.6 mm. ONC201 (MedKoo Bioscience, Morrisville,
NC) was administrated daily through intraperitoneal (IP) injection at 50 mg/kg.
Animals were sacrificed 7 days after the IC injection.
Isolation and culture of primary MDM, PBL and microglia, and U1 cells
Human monocytes and peripheral blood lymphocytes were isolated by
counter-current centrifugal elutriation from peripheral blood mononuclear cells
obtained through leukopheresis from healthy donors (96).
Primary monocytes were cultured as adherent monolayers at a density of
1.1 x 106 cells/well in 24-well plates or 0.25 x 106 cells/well in 96-well plates and
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differentiated for 7 days in differentiation medium consisting of Dulbecco’s
Modified Eagle’s Medium (DMEM) (Sigma Chemical Co., St. Louis, MO)
supplemented with 10% human serum, 50 µg/ml gentamicin (GIBCO Invitrogen
Corp.), 10 µg/ml ciprofloxacin (Thermo Fisher Scientific, Waltham, MA), and
1000 U/ml recombinant human macrophage-colony stimulating factor (M-CSF).
After 7 days in differentiation, the cells became MDM and M-CSF was removed
since the culture can produce M-CSF through autocrine secretion.
Primary PBL (1 x 106 cells) were stimulated with 20 ng/mL PMA (Sigma
Chemical Co., St. Louis, MO) and 1 M ionomycin (Sigma Chemical Co., St.
Louis, MO) in 10 mL of Roswell Park Memorial Institute (RPMI) 1640 (GE
Healthcare Life Sciences, Logan, UT) for 5 hours and then moved to RPMI 1640
media supplemented with 10% fetal bovine serum, 2 mM glutamine (Sigma
Chemical Co., St. Louis, MO), 50 ng/mL recombinant IL-2 (R&D Systems,
Minneapolis, MN) and antibiotics for further growth.
Human fetal microglia were prepared from a mixed culture of fetal brain
tissue-derived microglia-astrocytes as previously described (97, 98). Enriched
microglia were plated and cultured in the presence of M-CSF for an additional 7
days before experiments.
U1 cell line was bought from NIH AIDS reagent program (Catalog
Number:165, Lot Number:100218) and cultured in RPMI 1640 containing 2.0
mM

L-glutamine,

90%;

heat-inactivated

fetal

recommended.
HIV-1 Infection of MDM and ONC201 treatment

bovine

serum,

10%

as
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MDM were infected with HIV-1ADA, a macrophage-tropic strain of HIV-1,
Clade B or Clade C at a multiplicity of infection (MOI) of 0.1 virus/target cell (96).
Briefly, viral stocks were diluted in MDM medium (same with the differentiation
medium but without M-CSF) for overnight incubation with MDM. On the second
day, medium was removed and substituted with MDM medium and either DMSO
(Sigma), ONC201, or ONC201 isomer (MedKoo Bioscience). For selected
experiments, a recombinant human TRAIL R2/Fc Chimera Protein (R&D
Systems, Minneapolis, MN) was added to the cultures along with ONC201. The
cultures were re-treated with the same drugs in fresh MDM medium every 2
days. At 4 days post-infection, the cultures were treated with the same drugs in
0.5 ml/well fresh serum-free NeurobasalTM medium (Thermo Fisher Scientific)
for 24 hours before all samples were collected.
Assessment of cell viability
MDM and glioblastoma (ATCC, CRL-1620) viability was determined by a
colorimetric CellTiter 96® AQueous One Solution Assay (Promega, Madison, WI)
based on the manufacture’s instruction. Assays were performed by adding 20 µl
of the CellTiter 96® AQueous One Solution Reagent, which contained a
tetrazolium compound[3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)2-(4-sulfophenyl)-2H-tetrazolium, inner salt; MTS] and an electron coupling
reagent (phenazine ethosulfate; PES), directly to each of 100 µl MDM medium
in 96-well plates. After 2-hour incubation at 37°C in a humidified 5% CO2
atmosphere, the absorbance of each well was recorded at 490 nm using a 96well plate reader (BioTek, Winooski, VT).
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HIV-1 reverse transcriptase (RTase) activity assay
HIV-1 replication levels were determined by HIV-1 RTase activity assay as
described previously (96). RT activity was determined in triplicate samples of
cell culture fluids. For this assay, 10 μl of supernatant was incubated in a
reaction mixture of 0.05% Nonidet P-40, 10 μg of poly(A)/ml, 0.25 μg of
oligo(dT)/ml, 5 mM DTT, 150 mM KCl, 15 mM MgCl2, and [3H]TTP in Tris-HCl
buffer (pH 7.9) for 24-h at 37 °C. Radiolabeled nucleotides were precipitated
with ice-cold 10% trichloroacetic acid on UniFilter-96 GF/C (FilterMate Harveser,
Waltham, MA) in an automatic cell harvester (FilterMate Harveser, Waltham, MA)
and washed with 95% ethanol. Radioactivity was determined by liquid
scintillation spectroscopy.
Western blots
MDM or tissues of injection sites were homogenized with a PowerGen
Homogenizer (Thermo Fisher Scientific) and then lysed by M-PER™
Mammalian Protein Extraction Reagent (Thermo Fisher Scientific, Waltham,
MA). Protein concentrations were determined by Bradford protein assay (BioRad, Hercules, CA). Cell lysates were subjected to SDS-PAGE to separate
proteins

and

electrophoretically

transferred

to

Polyvinylidene

fluoride

membranes (Bio-Rad, Hercules, CA). Membranes were incubated overnight at
4 °C with polyclonal antibodies for FOXO3a (Cat#, 75D8, Cell Signaling
Technology, Danvers, MA), phosphorylated FOXO3a (Cat#, 9466s, Cell
Signaling Technology, Danvers, MA), HIV-1 p24 (Ref#, M0857, DAKO Corp,
Carpinteria, CA), human CD68 (Ref#, M0876, DAKO Corp, Carpinteria, CA),
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and β-actin (Sigma-Aldrich, St. Louis, MO), followed by horseradish peroxidaselinked secondary anti-rabbit or anti-mouse secondary antibodies (Cell signaling
Technology, Danvers, MA). Antigen-antibody complexes were visualized by
Pierce ECL Western Blotting Substrate (Thermo Fisher Scientific). For
quantification of the data, films were scanned with a CanonScan 9950 F
scanner (Canon Inc., Tokyo, Japan) and images were analyzed using the public
domain NIH Image J program (developed at the U.S. National Institutes of
Health and available on the internet at http://rsb.info.nih.gov/nih-image/).
RNA and DNA extraction and real time RT-PCR analysis of HIV-1 gag
Total RNA was isolated with TRIzol Reagent (Thermo Fisher Scientific) and
RNeasy Mini Kit according to the manufacturer’s protocol (Qiagen Inc., Valencia,
CA). Following RNA extraction, DNA was isolated from the remaining organic
phase using the DNeasy Blood and Animal Spin-Column kit according to
manufacturer’s instructions (Qiagen). Assays-on-demand primers for TRAIL (ID#,
Hs00921974_m1),

FOXO3a

(ID#,

Hs00818121_m1),

18S

rRNA

(Ref#,

4352930#) and GAPDH (ID#, Hs01922876_u1) were purchased from Thermo
Fisher Scientific. For quantification of HIV-1 gag, primers and probe were
purchased from Thermo Fisher Scientific with the following sequences: forward,
5’ ACA TCA AGC CAT GCA AAT-3’; reverse, 5’-ATC TGG CCT GGT GCA ATA
GG-3’; probe, 5’-FAM-CAT CAA TGA GGA AGC TGC AGA ATG GGA TAG ATAMRA-3’. Real-time reverse-transcription polymerase chain reaction (RT-PCR)
was performed in a volume of 10 µl using the one-step quantitative TaqMan
Real-time RT-PCR system (Applied Biosystems Inc.). For analysis of HIV-1 gag
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DNA, real-time PCR was carried out directly on the DNA samples using the
TaqMan Universal Master Mix and a StepOne Plus Real-Time PCR System
(Thermo Fisher Scientific). Relative FOXO3a, TRAIL, CD4, CCR5 and HIV-1
gag levels were determined and standardized with GAPDH or 18S rRNA internal
control using comparative ∆∆CT method. All primers used in the study were
tested for amplification efficiencies and the results were similar.
Analysis of HIV-1 proviral DNA integration
Two-step nested PCR assays were used for quantitative HIV-1 DNA
integration analysis as previously described (99, 100). The first round was
performed in a 25 µl reaction mix to pre-amplify the genomic DNA from infected
macrophages. The following primers were used: Alu forward, 5’-GCC TCC CAA
AGT GCT GGG ATT ACA G-3’; and HIV-1 gag reverse, 5’-GCT CTC GCA CCC
ATC TCT CTC C-3’. The PCR reaction contained 10x EX Taq Buffer, dNTP mix
(2.5 mM), EX Taq (all from TaKaRa Bio Inc., Otsu, Shiga, Japan), ddH2O, 100
nM Alu forward primer, 600 nM gag reverse primer, and 100 ng of genomic DNA.
The DNA Engine Peltier Thermal Cycler (Bio Rad, Hercules, CA) was
programmed to perform a 2-minute hot start at 94°C, followed by 30 steps of
denaturation at 93°C for 30 second, annealing at 50°C for 1 minute, and
extension at 70°C for 2 minutes. The second round real-time quantitative PCR
was performed by using 5.6 µl of the reaction mix from the pre-amplification step.
The amplified DNA was standardized with an internal GAPDH control. The
sequences of the primers and probe were as follows: LTR forward, 5’-GCC TCA
ATA AAG CTT GCC TTG A-3’; LTR reverse, 5’ -TCC ACA CTG ACT AAA AGG
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GTC TGA-3’; probe: 5’-FAM-GCG AGT GCC CGT CTG TTG TGT GAC TCT
GGT AAC TAG CTC GC-BHQ-3’.
P24 and TRAIL ELISAs
Supernatants collected at 5 days post-infection were analyzed for p24 and
TRAIL levels by in-house ELISAs (paired antibodies, R&D Systems,
Minneapolis, MN) as previously described (101).
Free-floating immunohistochemistry and image analyses
Animals were euthanized under deep anesthesia and perfused with
phosphate-buffered saline (PBS) and then with 4% paraformaldehyde (PFA) in
PBS. The brains were removed and immersed in freshly depolymerized 4% PFA
in PBS for 48 h and then cryoprotected by 30% sucrose for 48 h. The fixed,
cryoprotected brains were frozen and sectioned in the coronal plane at 30
microns using a Cryostat (Leica Microsystems Inc., Bannockburn, IL), with
sections collected serially in PBS as previously described (102). Brain sections
were then incubated overnight at 4 °C with primary antibodies, followed by
secondary antibodies (Molecular Probes, Eugene, OR, 1:1000) for 1 h at 25 °C.
Primary antibodies included P24 (DAKO, 1:1000) and human CD68 (DAKO, 1:
1000). All antibodies were diluted in 5% goat serum in PBS. Cells were
counterstained with DAPI (Sigma-Aldrich, 1:2000) to identify the nuclei. Images
were taken using a Zeiss Meta 710 confocal microscope (Carl Zeiss
MicroImaging, LLC) (20× object, tile scan 4 × 4 mode). Section images from
eight mice were imported into Image-ProPlus, version 7.0 (Media Cybernetics,
Silver Spring, MD) for quantification of p24/DAPI and CD68/DAPI double
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positive staining. The assessors were blinded during image acquisition and
quantification.
Statistical analysis
Data are expressed as means ± SD unless otherwise specified. Statistical
analysis was performed by using one-way ANOVA, followed by the Tukey’spost-test for paired observations, or two-way ANOVA when two independent
variables are considered. The two-tailed Student’s t test was used to compare
two groups. Significance was determined by a p value < 0.05. All experiments
were performed with cells from at least three donors to account for any donorspecific differences. Assays were performed at least three times in triplicate or
quadruplicate within each assay.
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2.4 Results
Anti-tumor agent, ONC201, is safe for uninfected macrophages and
lymphocytes
Because ONC201 was originally identified as a TRAIL-inducing anti-tumor
agent (78), we first sought to confirm its activity in tumor and transformed cells.
We treated A-172 human glioblastoma cells, Hela cells and 293T cells with
doses of ONC201 or its isomer ranging from 0.03 to 30 μM for 72 hours and
then determined the cell viability through an MTS assay (Fig. 2.1). Treatment
with ONC201, but not ONC201 isomer induced dose-dependent cytotoxicity in
glioblastoma cells, Hela cells and 293T cells, confirming the bioactivity of
ONC201.
Next, to determine the safe dose of ONC201 for macrophages and
lymphocytes, we treated MDM and PBL with either ONC201 or its isomer for 5
days at concentrations ranging from 0.03 to 30 μM. Treatment with either
ONC201 or its isomer did not significantly change cell viability of MDM and PBL
at all concentrations tested, as measured by MTS assays (Fig. 2.2). Even at the
highest soluble concentration, 30 μM, ONC201 is safe for human primary
macrophages and lymphocytes.
ONC201

activates

FOXO3a

and

induces

TRAIL

expression

in

macrophages.
There are two forms of FOXO3a: the phosphorylated form is inactive and
kept in the cytoplasm; once dephosphorylated, it moves to the nucleus and
becomes active, inducing pro-apoptotic genes. To assess the status of FOXO3a
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in HIV-1 infected macrophages after ONC201 treatment, the levels of total
FOXO3a, phosphorylated FOXO3a and β-actin were measured by Western
blots (Fig. 2.3). After quantification, we found the phosphorylation of FOXO3a,
determined by the ratio of phosphorylated FOXO3a over total FOXO3a, was
decreased after ONC201 treatment compared with treatments of the isomer and
DMSO controls. This result indicates that FOXO3a is dephosphorylated and
activated by ONC201 in HIV-1 infected MDM. Next, the soluble TRAIL in the
culture supernatant was measured by ELISA. After adjusted to intracellular
protein concentrations, the result showed dose-dependent increased levels of
soluble TRAIL after ONC201 treatment compared with those after treatment of
the isomer or DMSO controls (Fig. 2.4). Thus, ONC201 activated FOXO3a and
induced the downstream expression of TRAIL in HIV-1 infected macrophages.
The findings in HIV-1 infected MDM provide us with the information of
overall changes of FOXO3a phosphorylation and TRAIL expression in infected
cells with the same settings to the following antiviral tests. However, these
changes might only be a consequence of differentiated HIV infection but not a
direct consequence of ONC201 treatment. Thus, the effect of ONC201 in
uninfected MDM also needed to be assessed. For this sake, MDM were treated
with ONC201 or its isomer at 3 to 30 μM for 5 days without HIV-1 infection.
Analysis of phosphorylation of FOXO3a and expression of TRAIL was the same
as that in infected MDM. We found that in uninfected MDM, ONC201 treatment
also reduced the phosphorylation of FOXO3a and increased the amount of
soluble TRAIL, which is consistent with the findings in HIV-1 infected MDM (Fig.
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2.5 and 2.6). This result confirms that ONC201 treatment is mainly responsible
for the activation of FOXO3a and induction of TRAIL expression in HIV-1
infected MDM.
ONC201 inhibits HIV-1 infection of macrophages in vitro
To explore the potential antiviral effect of ONC201 on macrophages, we
infected MDM with HIV-1ADA, a macrophage-tropic strain of HIV-1, for 24 hours
and then treated cells with doses of ONC201 or its isomer ranging from 0.03 to
30 μM. At 5-day post treatment when HIV-1ADA replication peaks in MDM,
supernatants were collected and subjected to HIV-1 RTase activity assay. This
assay determines the levels of reverse transcriptase activity in cultural
supernatants and is a semi-quantitative measurement of HIV-1 replication levels
(103). Measured by RTase activity assay, the levels of HIV-1 viral replication
were significantly decreased in the ONC201-treated groups in a dosedependent manner from 3 to 30 μM, compared with those in the isomer-treated
groups as control (Fig. 2.7). Therefore, ONC201 has a specific antiviral activity
against HIV-1 in human MDM.
To further confirm the antiviral effect of ONC201 in MDM, we determined
the levels of both intracellular and extracellular HIV-1 capsid protein p24 through
Western blots on cell lysates and ELISA on culture supernatants respectively.
Treatment with ONC201 significantly decreased the amount of p24 in the
infected MDM on both intracellular and extracellular levels (Fig. 2.8). Consistent
with the p24 data, treatment with ONC201 significantly decreased the levels of
HIV-1 gag RNA and DNA when compared with those in the isomer or DMSO
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groups (Fig. 2.9A and B). Furthermore, we determined the HIV-1 integration
through a two-step Alu-based nested PCR method and found that treatment with
ONC201 significantly decreased the level of integrated HIV-1 DNA in MDM
when compared with those in isomer or DMSO groups (Fig. 2.9C). Together,
ONC201 appears to reduce multiple viral intermediates and products in HIV-1
lifecycle.
To confirm this antiviral effect of ONC201 on other HIV strains in
macrophages, we infected MDM with two HIV Clade B strains, G0048CPX and
2562BG, and one HIV Clade C strain, 2873MVC, respectively and then treated
cells with doses of ONC201 or its isomer for 14 days. For all three strains,
ONC201 treatment at the concentration of 10 and 30 μM reduced the viral
replication at 10-day post infection when compared with isomer treatment, which
is consistent with the results in HIV-1ADA (Fig. 2.10). In addition, ONC201
treatment at the concentration of 3 μM also decreased viral replication for HIV
Clade C strain, though the same treatment did not affect viral replication for
other two HIV Clade B strains. These results showed that the anti-HIV-1 activity
of ONC201 is applicable to different natural HIV strains that can infect MDM.
ONC201 inhibits HIV-1 infection in lymphocytes, microglia and latently
infected cell line in vitro
Lymphocytes and microglia are also HIV-1 reservoir cells in the CNS. To
test the antiviral activity of ONC201 in these cells, we infected human PBL and
microglia with HIV-1 for 7 and 1 day respectively, followed by 5-day treatment of
ONC201 or its isomer. Analysis of HIV-1 replication in PBL and microglia by
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RTase activity assay demonstrated similar results to those seen in MDM, that
ONC201 treatment significantly reduced HIV-1 replication at the concentrations
over 3 μM in these two cell types, indicating ONC201 is an effective agent to
limit HIV-1 replication in all three major reservoir cell types in CNS (Fig. 2.11).
Pro-monocytic U1 cells, latently infected with HIV-1, can be stimulated by
TNF to reactivate the virus from latency. To study the effect of ONC201 on the
reactivated HIV-1 in latently infected cell line, we treated U1 cells with ONC201
or its isomer in the presence of TNF and measured the viral production by
RTase activity assay and ELISA. Two assays both showed that ONC201
treatment decreased the level of reactivated HIV-1 in the culture supernatant
(Fig. 2.12). This inhibitory effect of ONC201 were seen at the concentrations as
low as 0.3 μM, suggesting a higher antiviral efficacy of ONC201 in these latently
infected cells compared with that in MDM.
ONC201 synergies with AZT in HIV-1 inhibition in vitro
Azidothymidine (AZT) is one of the most frequently used reverse
transcriptase inhibitors in vitro. To determine whether the combination of AZT
and ONC201 could further improve the anti-HIV-1 effect of both drugs, HIV-1
infected MDM were incubated with doses of AZT along with either ONC201 or
its isomer. We found that addition of ONC201 shifted the inhibitory curve of AZT
leftward compared with addition of its isomer, with the half maximal effective
concentration (EC50) decreasing from 0.15 μM to 0.015 μM (Fig. 2.13). This
potentiation indicates that ONC201 synergies with AZT in HIV-1 inhibition.
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AZT has a potent inhibition on HIV-1 replication in macrophages. However,
viral replication usually rebounds in days after the AZT treatment discontinues.
To test whether ONC201 treatment could prolong the viral suppression
established by AZT, HIV-1 infected MDM were incubated with AZT along with
either DMSO, ONC201 or its isomer for 6 days. The treatment was ceased at 7day post infection (dpi). We observed that the viral rebound occurred at 11 dpi in
DMSO and isomer treated groups while no viral rebound was seen in ONC201
treated group even at 15 dpi, indicating addition of ONC201 to AZT treatment
achieves longer viral suppression after the treatment was interrupted (Fig. 2.14).
ONC201 has an anti-HIV-1 effect on macrophages in vivo
To further determine whether ONC201 has an anti-HIV-1 effect in vivo, we
used an established HIV-1 infected NOD/SCID/IL2Rγcnull (NSG) model (104106). HIV-1 infected human MDM were intracranially injected into basal ganglion
of the NSG immunocompromised mice. At 24-h post MDM engraftment, the
mice were administrated daily with either ONC201 (50 mg/kg) or vehicle control
via intraperitoneal (IP) for six days. At 7-day post MDM engraftment, the mice
were sacrificed for HIV-1 detection (Fig. 2.15).
To visualize the HIV-1-infected cells in basal ganglion, we first performed
immunohistochemistry in serial para-coronal brain slices encompassing the
injection track with DAPI (Fig. 2.16A and D) and p24 (Fig. 2.16B and E). Both
DAPI and p24 clearly marked the injection tracks and their signals were in close
proximity to each other in the injection tracks (Fig. 2.16C and F). To confirm that
the p24-positive cells are CD68-positve macrophages, we performed CD68
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staining. Because CD68 and p24 antibodies are from the same species (mouse)
and alternative antibodies from other species worked poorly in the coimmunostaining (data not shown), we individually labeled the injection site with
either CD68 or p24 along with DAPI. CD68 staining revealed a substantial
number of macrophages remained in the injection track in both DMSO and
ONC201 treatment groups (Fig. 2.16G and H). We quantified the p24-positive
and CD68-positive cells in consecutive slides through a previously established
stereological method (107, 108). As expected, we observed that ONC201
administration significantly decreased p24-positive cells as a percentage to total
CD68-positive cells (Fig. 2.16I), compared with those in the vehicle control
group. These data suggest that ONC201 reduces the number of HIV-1-infected
macrophages in the in vivo NSG mouse model.
In order to better quantitatively determine the levels of HIV-1 inhibition, we
homogenized the tissues that contained injection sites and subjected the tissue
lysates to Western blots (Fig. 2.17A). The quantification data revealed that p24
levels significantly decreased in the ONC201 group compared with the control
group (Fig. 2.17B). In contrast, CD68 levels were comparable in all of the brain
lysates. As a result, the ratio of p24 to CD68 significantly decreased after
ONC201 treatment (Fig. 2.17C), which is consistent with the p24 and CD68
staining data. Together, these data in HIV-1-infected NSG mice demonstrated
that ONC201 is able to inhibit HIV-1 infection of macrophages in vivo.
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2.5 Discussion
Termination of long-term HIV persistence by eliminating viral reservoirs is
essential to combat AIDS in the post-ART era (109-111). In the present study,
ONC201 was tested for its potential antiviral effect on the HIV-1 infected CNS
reservoir cells. We demonstrated that ONC201 has little toxicity in uninfected
human macrophages and lymphocytes and exert an anti-HIV-1 effect on
infected macrophages, lymphocytes, microglia and U1 cell line in vitro. This
antiviral activity of ONC201 is applicable not only to macrophage-tropic HIV
strain but also to other broadly spread HIV strains. When combined with
ONC201, AZT achieves a synergic antiviral effect and a longer viral suppression
without viral rebound. In a murine HIV Encephalitis model, ONC201 treatment
significantly reduced HIV-1 levels in transplanted macrophages, indicating the
antiviral effect of ONC201 against HIV brain reservoirs in vivo.
Although variants of recombinant TRAIL and the longer-lived TRAIL
receptor agonist antibodies have been developed and applied in clinical trials
(112-118), those protein-based therapeutics are costly and the therapeutic
concentrations remain difficult to maintain. Therefore, increasing endogenous
TRAIL protein production via pharmacological means is an attractive approach.
ONC201 was originally screened from the National Cancer Institute (NCI)
Diversity Set II as one of the small molecules capable of up-regulating
endogenous TRAIL gene transcription (77). There are other potent TRAILinducing compounds such as TIC9 reported from the screening. However,
ONC201 seems to uniquely potentiates tumor cell death while sparing normal
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cells and lacks genotoxicity in normal fibroblasts, which could be the result of a
relatively milder induction of death receptor 5 compared with those inducted by
TIC9 (77). This characteristic of ONC201 allows it to specifically target HIV-1
infected macrophages and be further considered for clinical applications.
ONC201 has been well-known in cancer research for its capacity to induce
sustained TRAIL upregulation and apoptosis in tumor cells both in vitro and in
vivo (77, 78). Our study for the first time demonstrates that ONC201 inhibits
HIV-1 replication in macrophages both in vitro and in vivo. The evidence for viral
inhibition after ONC201 treatment is multifold. First, the HIV-1 RTase activity
assay is a relatively accurate measurement of HIV-1 virion production in the
supernatants (103). In our study, the result of this measurement was confirmed
by ELISA on the HIV-1 p24 in the same supernatants. Second, two-step Alubased nested PCR determines the level of HIV-1 integration by measuring HIV1 LTR DNA as the proviral DNA integrated in the host genome (119). ONC201
is able to lower the levels of HIV-1 integration into the genome. Third, ONC201
also decreases intracellular p24, GAG RNA, and GAG DNA in HIV-1-infected
MDM.
Furthermore, this antiviral effect of ONC201 is not limited to HIV-1ADA in
macrophages, but also applicable to other HIV strains and other reservoir cell
types. HIV-1ADA is a macrophage-tropic HIV-1 strain. After laboratory adaption,
its ability to infect macrophage is further enhanced so that its infection in
macrophage typically peaks at 5-day post infection. This characteristic allows
HIV-1ADA to be one of the optimal HIV strains to study HIV-1 infection in
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macrophages. Apart from HIV-1ADA, HIV Clade B and C strains can also infect
macrophages. In our study, the infection of two HIV Clade B strains in MDM
peaked at around 10-day post infection whereas the HIV Clade C strain may still
have not reached its highest infection at 14-day post infection. For 2873MVC
and 2562BG strains, the antiviral effect of ONC201 started to be observed at 10day post infection, and a nearly full viral suppression by ONC201 was seen at
14-day post infection, showing an even more potent antiviral effect than that in
HIV-1ADA. Based on the inhibitory curves of ONC201 in these HIV strains, the
EC50 of ONC201 for HIV-1ADA and HIV Clade C is around 3 μM while the EC50
for HIV Clade B is between 3 and 10 μM. This suggests that ONC201 is of
higher efficacy for HIV Clade C than for HIV Clade B.
Microglia and lymphocytes are other major cell types of HIV-1 reservoir.
Microglia, though usually regarded as the resident macrophages in CNS,
possess distinct phenotype compared with MDM. Fate-mapping studies of
macrophage populations in the body have determine that microglia are not
derived from the bone marrow but originate from erythromyeloid precursors
early in the embryonic development (120, 121). The effective concentrations of
ONC201 found in human primary microglia are similar to those in MDM,
suggesting that both CNS reservoir cells can benefit from the same therapeutic
doses of ONC201 in clinical application. Memory CD4+ T cells form the HIV-1
reservoirs outside CNS. ONC201 inhibits HIV-1 infection in infected PBL and
has no cytotoxicity on uninfected PBL at the effective concentrations, suggesting
the application of ONC201 as an anti-HIV-1 agent may not be limited to CNS but
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be general to the circulation and other organs. Thus, future in vivo study of
ONC201 on lymphocytes in peripheral blood, spleen, gut and lymph nodes is
needed.
Despite its specific effect on HIV-1 replication, at the current working
concentration (30 μM), ONC201 is not able to completely eradicate HIV-1 from
the cultures. This could be due to the expression of TRAILshort in MDM that
confers TRAIL resistance upon ONC201 treatment (122), or lack of optimal
trimeric TRAIL conformation that is most potent for the antiviral effect (123). To
achieve an even more potent antiviral effect, a higher concentration of ONC201
might be needed. However, ONC201 is only soluble in DMSO but not in water.
In our study, ONC201 is soluble in DMSO up to 25 mM. In order to achieve
ONC201 concentrations above 30 μM in MDM cultures, at least 0.1% final
concentration (v/v) of DMSO will be used, which may cause cytotoxicity,
potentially affecting the observation and interpretation of the specific antiviral
effect of ONC201. Thus, we used 30 μM as the highest test concentration for
ONC201 in the experiments. To further increase the solubility of ONC201 in
DMSO and water, modifications on the structure of ONC201 or a nanoparticlemediated delivery of ONC201 should be considered for the future study.
For a complete HIV-1 eradication, another strategy is to use a combination
of anti-HIV-1 drugs targeting different steps in the process of viral infection. AZT
is one of the classic drugs in Highly Active Antiretroviral Therapy (HAART) that
aims to prevent HIV resistance. As a thymidine analogue, AZT selectively
inhibits the reverse transcriptase of HIV-1. Although AZT itself can effectively
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inhibit HIV-1 replication in macrophages in vitro, viral rebound occurs days after
drug withdrawal. In our study, ONC201 left-shifted the inhibitory curve of AZT in
HIV-1 infected MDM, showing a potentiation on the antiviral effect of AZT. When
combined with ONC201, AZT achieved a longer HIV-1 suppression after drug
withdrawal. The mechanism underlying this synergy needs to be further
investigated.
One of the most commonly used in vitro models to study HIV-1 latency in
macrophage is U1 cells. As a subclone of U937, which is a pro-monocyte
obtained from diffuse histiocytic lymphoma, U1 is latently infected with HIV-1
(124). It contains two integrated copies of the viral genome but shows minimal
constitutive expression of virus (124). Under certain stimulated conditions, such
as TNF and PMA treatment, latent virus can be reactivated and secreted into
the medium (125). With analysis of both p24 and HIV-1 reverse transcriptase
activity in the medium, we observed a potent viral inhibition by ONC201 in TNFstimulated U1 cells, suggesting an antiviral effect of ONC201 in macrophages
containing latent virus. However, this effect may not be attributed to the
cytotoxicity of ONC201 in U1 cells, because we did not observe a significant
decrease of cell viability in stimulated U1 cells with ONC201 treatment (data not
shown). Instead, the ability of ONC201 to inactivate Akt-1 could play a major
role in this process. Previous study on the mechanism of viral reactivation in U1
cells has shown that the activation of Akt in host cells is critical in the
reactivation of latent virus (125). Thus, Akt activators such as disulfiram were
used to reactivate the latent virus in the strategy of “shock and kill” (126), while
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Lopinavir/Ritonavir limits HIV-1 reactivation via blocking the Akt pathway in the
strategy of “block and lock” (125). ONC201 also inactivates Akt, thus possibly
preventing the latency virus in TNF-stimulated U1 cells from reactivation in the
strategy of “block and lock”. However, the real scenario of HIV-1 latency in
macrophages may differ from the artificial latency established in chronically
infected U1 cells. Further study on the Akt pathway in HIV-1 latency is needed
for better interpreting the antiviral effect of ONC201 in latently infected cells.
As a small molecule, ONC201 shows an outstanding capability of BBB
penetration, which makes it particularly attractive for combating CNS viral
reservoirs. For brain tumors such as glioblastoma, ONC201 penetrates the
intact BBB with 5 times higher concentrations in brain tissue relative to plasma
in rodents (78). Therefore, after a successful dose escalation phase I trial (127),
many ongoing clinical trials (clinicaltrials.gov) focus on brain tumors. In the
present study, ONC201 is injected through IP into the NSG mice and its antiviral
effect against the HIV-1-infected macrophages in the brains indicate that it is
able to cross the BBB and achieve the therapeutic outcome in the case of CNS
HIV-1 infection.
Immune-activating agents, such as interleukin 2 and anti-CD3 antibody, or
for epigenetic modulation, such as HDACs inhibitors, often failed to purge the
virus in vivo (31, 128-131). Therefore, new therapeutic agents are warranted to
combat persistent HIV-1 infection. Our study demonstrates for the first time that
ONC201, a FOXO3a activator and TRAIL inducer, inhibits HIV-1 replication in
macrophages both in vitro and in vivo. Notably, ONC201 is the founding
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member of the imipridone class of compounds that share a unique imidazo
pharmacophore. New compounds continue to be developed in this class (132,
133). These new group of compounds provide us with more drug candidates to
modulate immunity and fight viral infections.
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2.6 Figures
Figure 2.1 ONC201 inhibits the proliferation of tumor and transformed
cells. Glioblastoma cell line A172 (A), 293T cell line (B) and Hela cell line (C)
were plated in 96-well plates in triplicate and then incubated with doses of
ONC201 or its isomer ranging from 0.03 to 30 μM. Cell viability was determined
by the MTS assay. Results shown are from representative experiments
performed with three different plates of cells. Data were analyzed by two-way
ANOVA: * denotes p < 0.05, ** denotes p < 0.01 and *** denotes p < 0.001.
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Figure 2.2 ONC201 does not change the cell viability of uninfected
macrophages and lymphocytes. Human monocyte-derived macrophages
(MDM) (A) and peripheral blood lymphocytes (PBL) (B) were plated in 96-well
plates and incubated with doses of ONC201 or its isomer ranging from 0.03 to
30 μM. At 5-day post ONC201 and isomer treatments, cell viability was
determined by the MTS assays. Data were analyzed by two-way ANOVA, and
results shown are the means ± SD of 3 experiments.
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Figure 2.3 ONC201 activates FOXO3a in HIV-1 infected macrophages.
Human MDM were plated in 24-well plates and then infected with HIV-1ADA for
24 hours before incubation with ONC201 or ONC201 isomer at 3 to 30 μM for 5
days. Cell lysates were collected and subsequently subjected to SDS-PAGE
and immunoblotting for the detection of phospho-FOXO3a and total FOXO3a.
Actin was used as the loading control. Densitometric quantifications of phosphoFOXO3a in MDM were presented as a ratio to total FOXO3a and normalized as
fold changes to the no treatment control. Values represent SEM of biological
replicates. ANOVA analysis: * denotes p <0.05 and ** denotes p < 0.01,
compared with the DMSO group.
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Figure 2.4 ONC201 induces TRAIL expression in HIV-1 infected
macrophages. Human MDM were plated in 24-well plates and then infected
with HIV-1ADA for 24 hours before incubation with ONC201 or ONC201 isomer at
3 to 30 μM for 5 days. Soluble TRAIL concentration (pg/mg) was determined
from cell culture supernatants using ELISA and adjusted to intracellular protein
concentrations. Values represent SEM of biological replicates. ANOVA analysis:
* denotes p <0.05 and ** denotes p < 0.01, compared with the DMSO group.
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Figure 2.5 ONC201 activates FOXO3a in uninfected macrophages.
Human MDM were plated in 24-well plates and then incubated with ONC201 or
ONC201 isomer at 3 to 30 μM for 5 days. Cell lysates were collected and
subsequently subjected to SDS-PAGE and immunoblotting for the detection of
phospho-FOXO3a and total FOXO3a. Actin was used as the loading control.
Densitometric quantifications of phospho-FOXO3a in MDM were presented as a
ratio to total FOXO3a and normalized as fold changes to the no treatment
control. Values represent SEM of biological replicates. ANOVA analysis: *
denotes p <0.05 and ** denotes p < 0.01, compared with the DMSO group.
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Figure

2.6

ONC201

induces

TRAIL

expression

in

uninfected

macrophages. Human MDM were plated in 24-well plates and then incubated
with ONC201 or ONC201 isomer at 3 to 30 μM for 5 days. Soluble TRAIL
concentration (pg/mg) was determined from cell culture supernatants using
ELISA and adjusted to intracellular protein concentrations. Values represent
SEM of biological replicates. ANOVA analysis: * denotes p <0.05 and ** denotes
p < 0.01, compared with the DMSO group.
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Figure 2.7 ONC201 has an antiviral effect on macrophages. Human
MDM were plated in 96-well plates and infected with HIV-1ADA for 24 hours
before incubation with doses of ONC201 or its isomer ranging from 0.03 to 30
μM. At 5-day post ONC201 and isomer treatments, supernatants were removed
and the replication levels of HIV-1 were monitored by RTase activity assay.
Results shown are from representative experiments performed with three
different donors. Data were analyzed by two-way ANOVA: * denotes p < 0.05, **
denotes p < 0.01 and *** denotes p < 0.001.
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Figure 2.8 ONC201 reduces HIV-1 p24 in HIV-1 infected macrophages.
Human MDM were plated in 24-well plates in triplicate and then infected with
HIV-1ADA for 24 hours before incubation with ONC201 or ONC201 isomer at 30
μM for 5 days. A) Cell lysates were collected and subjected to SDS-PAGE and
immunoblotting for HIV-1 p24. Actin was used as the loading control.

B)

Supernatants were collected and subjected to ELISA for HIV-1 p24. Values
represent SEM of biological replicates. ANOVA analysis: * denotes p <0.05
compared with DMSO group.
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Figure 2.9 ONC201 reduces HIV-1 gag RNA, DNA, and integrated LTR
DNA in HIV-1 infected macrophages. Human MDM were plated in 24-well
plates in triplicate and then infected with HIV-1ADA for 24 hours before incubation
with ONC201 or ONC201 isomer at 30 μM for 5 days. RNA (A) and DNA (B, C)
were isolated and HIV-1 gag was detected through quantitative real time RT–
PCR and real time PCR, respectively.

Relative HIV-1 gag levels were

determined and standardized with 18S rRNA or GAPDH internal control. Values
represent SEM of biological replicates. ANOVA analysis: * denotes p <0.05
compared with DMSO group; ## denotes p < 0.01 compared with ONC201
treatment group.
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Figure 2.10 ONC201 has an antiviral effect on different HIV strains.
Human MDM were plated in 96-well plates and infected with different HIV
strains, i.e. 2873MVC (a HIV Clade C strain, A), G0048CPX (a HIV Clade B
strain, B) and 2562BG (a HIV Clade B strain, C) for 24 hours before incubation
with doses of ONC201 or its isomer ranging from 3 to 30 μM. At 2-, 6-, 10-, and
14-day post ONC201 and isomer treatments, supernatants were collected and
the replication levels of HIV-1 were monitored by RTase activity assay. Values
represent SEM of biological replicates. Data were analyzed by two-way ANOVA:
* denotes p < 0.05, ** denotes p < 0.01 and *** denotes p < 0.001.
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Figure 2.11 ONC201 inhibits HIV-1 replication in lymphocytes and
microglia. Human PBL (A), and microglia (B) were infected with HIV-1 ADA for
7 and 1 day, respectively, and then incubated with or without various doses of
ONC201 and ONC201 isomer for 5 days. The infection levels of HIV-1 were
monitored by RTase activity assay. Results shown are representative
experiments performed with three different donors. ANOVA analysis: * denotes
p < 0.05 and ** denotes p < 0.01, compared to DMSO group; # denotes p < 0.05,
## denotes p < 0.01, compared to the ONC201 treatment group at the same
dose.
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Figure 2.12 ONC201 has an antiviral effect on latently HIV-1-infected
cells. U1 cells were plated in 96-well plates and incubated with doses of
ONC201 or its isomer ranging from 0.01 to 100 μM in the presence of TNF (10
ng/mL). At 5-day post ONC201 and isomer treatments, supernatants were
removed and the replication levels of HIV-1 were monitored by RTase activity
assay (A) and ELISA (B). Results shown are from representative experiments
performed with three different plates of cells. Data were analyzed by two-way
ANOVA: * denotes p < 0.05, ** denotes p < 0.01 and *** denotes p < 0.001.

HIV-1 RTase activity
(cpm/ml X 102)

59

40000

Isomer
DMSO

30000

ONC201 3mM
ONC201 30mM

20000
10000
0

0

-8.0 -7.5 -7.0 -6.5 -6.0 -5.5 -5.0 -4.5
AZT Log[M]

Figure 2.13 ONC201 synergies with AZT in HIV-1 inhibition. HIV-1
infected MDM were incubated with doses of AZT ranging from 0.015 to 15 μM
along with either DMSO, ONC201 (3 μM or 30 μM), or ONC201 isomer (30 μM)
for 5 days. ONC201 isomer was used as a control for ONC201. The infection
levels of HIV-1 were monitored by RTase activity assay. Results shown are from
representative experiments performed with three different plates of cells.
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Figure 2.14 Addition of ONC201 to AZT treatment achieves a longer
viral suppression during viral rebound. MDM were infected with HIV-1ADA for
1 day and then incubated with 1 μM AZT along with either DMSO, ONC201 (30
μM), or ONC201 isomer (30 μM) for 6 days. The treatment was ceased at 7-day
post infection (dpi). The infection levels of HIV-1 were monitored by RTase
activity assay during and after treatment. Results shown are from representative
experiments performed with three different plates of cells. Data were analyzed
by two-way ANOVA: * denotes p < 0.05, ** denotes p < 0.01 and *** denotes p <
0.001.
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Figure 2.15 Timeline of experimental procedures and sample
collection in the HIV-1-infected NSG mouse model. HIV-1-infected human
macrophages were intracranially injected into the basal ganglia of NOD/scid-IL2Rcnull (NSG) mice. Mice were administrated daily with ONC201 (50 mg/kg) or
solvent control DMSO through intraperitoneal injections for six days. At the
seventh day, the mice were sacrificed for either immunostaining or Western blot
to measure the levels of HIV-1 P24 and CD68.
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A. CTL DAPI

B. CTL P24

C. CTL P24/DAPI

D. ONC201 DAPI

E. ONC201 P24

F. ONC201 P24/DAPI

G. CTL CD68/DAPI

H. ONC201 CD68/DAPI

I.

ONC201

Figure 2.16 ONC201 reduces HIV-1 infection levels in mouse brains
xenotransplanted

with

infected

human

macrophages

(shown

by

immunostaining). Immunostaining of p24 and CD68 in the injection sites of
mouse brains: co-immunostaining of p24 and DAPI (A-F); co-immunostaining of
CD68 and DAPI (G-H); quantification of the p24/CD68 ratio per area (I). Data
were evaluated statistically by an unpaired t-test, n = 6 per treatment group.
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Figure 2.17 ONC201 reduces HIV-1 infection levels in mouse brains
xenotransplanted with infected human macrophages (shown by Western
blots). Brain tissues that contained the injection sites were homogenized for
detection of HIV-1 p24 and human CD68 in Western blots: A) bands; B)
quantification of the p24/ β-actin ratio; C) quantification of the p24/ β-actin ratio.
Data were evaluated statistically by an unpaired t-test, n = 6 per treatment group.
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CHAPTER 3
FOXO3a-TRAIL Pathway Mediates the Antiviral Effect of ONC201.
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3.1 Abstract
ONC201 has been well-known in cancer research for its capacity to induce
sustained TRAIL upregulation and apoptosis in tumor cells in vitro and in vivo. It
inactivates both Akt and ERK to dephosphorylate FOXO3a so that FOXO3a can
move to nucleus to induce the transcription of TRAIL in cancer cell lines.
Macrophages express FOXO3a and TRAIL, which participate in the apoptosis
and autophagy during HIV-1 infection. The activation of FOXO3a and induction
of TRAIL by ONC201 in HIV-1 infected macrophages have been confirmed by
Western blots and ELISA respectively. We hypothesize that the anti-HIV-1 effect
of ONC201 is mediated by FOXO3a-TRAIL pathway. Blocking TRAIL with
soluble TRAIL receptor or knockdown of FOXO3a with siRNA reversed
ONC201-mediated HIV-1 suppression, indicating that ONC201 suppresses HIV1 through FOXO3a and TRAIL. The viral inhibition after pretreatment of
ONC201, as shown by RTase assay, is associated with apoptosis and cell death,
as shown by capspase-3 immunoblots and cell viability assay on the same
samples. Meantime, ONC201 induced autophagy in macrophages and blocking
autophagy by PI3K

inhibitor 3-MA

reversed

ONC201-mediated

HIV-1

suppression, suggesting that autophagy may also play a role in the antiviral
effect of ONC201. In addition, ONC201 did not change the expression of HIV-1
receptor and co-receptor, CD4 and CCR5, and HIV-suppressive chemokines,
RANTES and MIP-1α, excluding that the antiviral activity of ONC201 is through
blocking viral entry or increasing autocrine of HIV-suppressive chemokines.
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3.2 Introduction
The persistence of HIV-1 reservoirs in the CNS is always an obstacle for
ART. Failing to eradicate virus in those long-lived, low-turnover macrophages
and microglia, ART itself cannot ensure a complete end of the infection. On the
opposite, the persistently-produced viral proteins and activated immune cells
may damage brain tissues, leading to HAND. One strategy, “prime, shock and
kill”, has been proposed to manage the infected reservoir cells. According to this
strategy, infected cells will be killed by selectively-induced apoptosis through
pharmacological interventions. Apoptosis-inducing drugs are abundant in cancer
biology since apoptosis is one of the targets for accurately killing cancer cells. It
is reasonable that those antitumor agents may also induce apoptosis in HIV-1
infected cells.
ONC201, as a TRAIL inducer, is one of such antitumor agents that has
been shown to preferentially kill cancer cells via apoptosis without affecting
normal cells(79). It is orally active and BBB-permeable (78). After the first-inhuman clinical trial, ONC201 has been confirmed well-tolerated with a
recommended dose of 625 administered orally every three weeks for the
ongoing phase II clinical trials (81, 127). Recently, we introduced this drug into
HIV field because TRAIL also induces HIV-1 infected macrophages for
apoptosis (66). We observed that ONC201 inhibited HIV-1 infection in
macrophages, microglia and lymphocytes in vitro and in mouse brains
xenotransplanted with infected human macrophages in vivo. However, the
mechanism underlying this antiviral effect is still unknown.
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Based on the current knowledge of the mechanism of action of ONC201
and the mechanism of HIV-1-induced apoptosis in macrophages, ONC201 may
inhibit HIV infection through several mechanisms.
First, ONC201 may take advantage of FOXO3a-TRAIL pathway to increase
the expression of TRAIL and kill infected cells through TRAIL-induced apoptosis.
FOXO3a and TRAIL mediate HIV-1-induced apoptosis in infected macrophages.
Knockdown of FOXO3a or blocking TRAIL protected macrophages from HIV-1
induced apoptosis (41, 66). In cancer cells, ONC201 inactivates Akt and ERK to
activate FOXO3a and induce the transcription of TRAIL (78). TRAIL binds to
TRAIL-R1 or -R2 on the membrane of infected cells to trigger the apoptosis.
Second, ONC201 may induce DR5 to promote apoptosis in infected cells.
DR5 is another name for TRAIL-R2. Previous study showed that ONC201
induces ER stress, which activates Activating Transcription Factor 4 (ATF4)/
C/EBP homologous protein (CHOP) through integrated stress response (79).
CHOP further targets DR5 to increase its expression (134). In HIV-1 infected
macrophages, DR5 is upregulated at the late stage of productive viral infection,
which is one of proposed mechanisms for TRAIL’s preferential killing profile on
infected macrophages (62, 66). ONC201 may further increase the expression of
DR5 to sensitize infected macrophages for apoptosis. Nevertheless, it is
possible that ONC201 induces apoptosis through other pathways downstream
to ER stress.
Third, ONC201 may utilize autophagy to inhibit HIV-1 infection. Autophagy
is one of the most ancient defense processes against invading pathogens.
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Evidences have shown that autophagy restricts HIV-1 infection in CD4 T cells,
monocytes and macrophages. In a clinical study in 2014, researchers found
PBMCs from HIV-infected long term non-progressors and elite controllers had
significantly higher levels of autophagy than normal progressors, suggesting
autophagy plays an important role in the containment of HIV-1 in nonprogressorinfected patients (135). In an in vitro study on HIV-1 infected macrophages, two
populations of autophagic cells were observed: one highly autophagic and the
other weakly autophagic. Surprisingly, viruses could be detected in the weakly
autophagic cells but not in the highly autophagic cells (136). The potential
mechanism could be that autophagy selectively degrades the HIV-1 Tat by
p62/SQSTM1 (137). Furthermore, autophagy-inducers such as Vitamin D3 and
Tat–beclin 1 peptide have been tested on HIV-1 infected macrophage and
shown to reduce the replication of HIV-1 in an autophagy-dependent manner
(138, 139). Notably, FOXO3a and TRAIL are also associated with autophagy.
FOXO3 stimulates the transcription of autophagy-related genes (LC3, Atg12,
Atg4, Beclin1, Gabarapl1, Ulk2, Bnip3, and Bnip3l) to increase autophagy and
lysosomal proteolysis(140-142). In addition, addition of recombinant TRAIL
triggered autophagy in human macrophage (143). Based on these evidences, it
is possible that ONC201 induces autophagy and inhibits HIV-1 replication in
macrophage through FOXO3a-TRAIL pathway.
Fourth, ONC201 as a DRD2 antagonist may reduce the dopaminepotentiated HIV-1 infection. Human macrophages express mRNA for all
dopamine receptor subtypes and protein for DRD1, DRD2, DRD3 and DRD4 in
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the plasma membrane (144, 145). Psychostimulants elevate the extracellular
dopamine levels in the CNS, which may facilitate HIV-1 infection in macrophage
and microglia, since dopamine treatment significantly increased HIV-1
replication in primary human macrophages though a D2-like dopamine receptor
(144). Another study showed that exposure to dopamine during infection
increased the entry of R5 tropic HIV into macrophages, and dopamine receptors
mediated this process (146).
ONC201 may inhibits HIV-1 infection through one or a combination of the
potential mechanisms listed above. Since the activation of FOXO3a and
induction of TRAIL expression by ONC201 in macrophages has been confirmed
in last chapter and we introduced ONC201 into HIV field with the expectation
that it should also induce apoptosis as it works in cancer cells, we first tested the
first potential mechanism. Knockdown of FOXO3a with siRNAs and blocking
TRAIL with soluble TRAIL receptors completely reversed the antiviral effect of
ONC201. We also observed a dose-dependently increased apoptosis in HIV-1
infected macrophages after pretreatment of ONC201. In addition, ONC201
induced autophagy in macrophages, and blocking autophagy via 3-MA reversed
the antiviral effect of ONC201, suggesting the autophagy might also be involved
as a mechanism.
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3.3 Materials and Methods
Ethics statement
Primary monocyte-derived macrophages

(MDM) were used in full

compliance with the University of Nebraska Medical Center and National
Institutes of Health ethical guidelines, with the Institutional Review Board (IRB) #:
162-93-FB.
Isolation and culture of primary MDM
Human monocytes were isolated by counter-current centrifugal elutriation
from peripheral blood mononuclear cells obtained through leukopheresis from
healthy donors (96).
Primary monocytes were cultured as adherent monolayers at a density of
1.1 x 106 cells/well in 24-well plates or 0.25 x 106 cells/well in 96-well plates and
differentiated for 7 days in differentiation medium consisting of Dulbecco’s
Modified Eagle’s Medium (DMEM) (Sigma Chemical Co., St. Louis, MO)
supplemented with 10% human serum, 50 µg/ml gentamicin (GIBCO Invitrogen
Corp.), 10 µg/ml ciprofloxacin (Thermo Fisher Scientific, Waltham, MA), and
1000 U/ml recombinant human macrophage-colony stimulating factor (M-CSF).
After 7 days in differentiation, the cells became MDM and M-CSF was removed
since the culture can produce M-CSF through autocrine secretion.
HIV-1 Infection of MDM and ONC201 treatment
MDM were infected with HIV-1ADA, a macrophage-tropic strain of HIV-1, at a
multiplicity of infection (MOI) of 0.1 virus/target cell (96). Briefly, viral stocks
were diluted in MDM medium (same with the differentiation medium but without
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M-CSF) for overnight incubation with MDM. On the second day, medium was
removed and substituted with MDM medium and either DMSO (Sigma),
ONC201, or ONC201 isomer (MedKoo Bioscience). For selected experiments, a
recombinant human TRAIL R2/Fc Chimera Protein (R&D Systems, Minneapolis,
MN) or 3-MA (Sigma Chemical Co., St. Louis, MO) was added to the cultures
along with ONC201. The cultures were re-treated with the same drugs in fresh
MDM medium every 2 days. At 4 days post-infection, the cultures were treated
with the same drugs in 0.5 ml/well fresh serum-free NeurobasalTM medium
(Thermo Fisher Scientific) for 24 hours before all samples were collected.
Assessment of cell viability
MDM viability was determined by a colorimetric CellTiter 96® AQueous One
Solution Assay (Promega, Madison, WI) based on the manufacture’s instruction.
Assays were performed by adding 20 µl of the CellTiter 96 ® AQueous One
Solution

Reagent,

which

contained

a

tetrazolium

compound[3-(4,5-

dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2Htetrazolium, inner salt; MTS] and an electron coupling reagent (phenazine
ethosulfate; PES), directly to each of 100 µl MDM medium in 96-well plates.
After 2-hour incubation at 37°C in a humidified 5% CO2 atmosphere, the
absorbance of each well was recorded at 490 nm using a 96-well plate reader
(BioTek, Winooski, VT).
HIV-1 reverse transcriptase (RTase) activity assay
HIV-1 replication levels were determined by HIV-1 RTase activity assay as
described previously (96). RT activity was determined in triplicate samples of
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cell culture fluids. For this assay, 10 μl of supernatant was incubated in a
reaction mixture of 0.05% Nonidet P-40, 10 μg of poly(A)/ml, 0.25 μg of
oligo(dT)/ml, 5 mM DTT, 150 mM KCl, 15 mM MgCl2, and [3H]TTP in Tris-HCl
buffer (pH 7.9) for 24-h at 37 °C. Radiolabeled nucleotides were precipitated
with ice-cold 10% trichloroacetic acid on UniFilter-96 GF/C (FilterMate Harveser,
Waltham, MA) in an automatic cell harvester (FilterMate Harveser, Waltham, MA)
and washed with 95% ethanol. Radioactivity was determined by liquid
scintillation spectroscopy.
Western blots
MDM or tissues of injection sites were homogenized with a PowerGen
Homogenizer (Thermo Fisher Scientific) and then lysed by M-PER™
Mammalian Protein Extraction Reagent (Thermo Fisher Scientific, Waltham,
MA). Protein concentrations were determined by Bradford protein assay (BioRad, Hercules, CA). Cell lysates were subjected to SDS-PAGE to separate
proteins

and

electrophoretically

transferred

to

Polyvinylidene

fluoride

membranes (Bio-Rad, Hercules, CA). Membranes were incubated overnight at
4 °C with polyclonal antibodies for Akt (Cat#, 9272S, Cell Signaling Technology,
Danvers, MA), phosphorylated Akt (Cat#, 9271S, Cell Signaling Technology,
Danvers, MA), ERK(Cat#, 9102, Cell Signaling Technology, Danvers, MA),
phosphorylated ERK (Cat#, 9101S, Cell Signaling Technology, Danvers, MA),
caspase-3 (Cat#, 9662S, Cell Signaling Technology, Danvers, MA), cleaved
caspase-3 (Cat#, 9664T, Cell Signaling Technology, Danvers, MA), LC3 A/B
(Cat#, 4108, Cell Signaling Technology, Danvers, MA), HIV-1 p24 (Ref#, M0857,
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DAKO Corp, Carpinteria, CA), human CD68 (Ref#, M0876, DAKO Corp,
Carpinteria, CA), and β-actin (Sigma-Aldrich, St. Louis, MO), followed by
horseradish peroxidase-linked secondary anti-rabbit or anti-mouse secondary
antibodies

(Cell signaling Technology,

Danvers, MA). Antigen-antibody

complexes were visualized by Pierce ECL Western Blotting Substrate (Thermo
Fisher Scientific). For quantification of the data, films were scanned with a
CanonScan 9950 F scanner (Canon Inc., Tokyo, Japan) and images were
analyzed using the public domain NIH Image J program (developed at the U.S.
National

Institutes

of

Health

and

available

on

the

internet

at

http://rsb.info.nih.gov/nih-image/).
RNA and DNA extraction and real time RT-PCR analysis
Total RNA was isolated with TRIzol Reagent (Thermo Fisher Scientific) and
RNeasy Mini Kit according to the manufacturer’s protocol (Qiagen Inc., Valencia,
CA). Following RNA extraction, DNA was isolated from the remaining organic
phase using the DNeasy Blood and Animal Spin-Column kit according to
manufacturer’s instructions (Qiagen). Assays-on-demand primers for TRAIL (ID#,
Hs00921974_m1),

FOXO3a

(ID#,

Hs00818121_m1),

CD4

(ID#,

Hs01058407_m1), CCR5 (ID#, Hs00152917_m1), 18S rRNA (Ref#, 4352930#)
and GAPDH (ID#, Hs01922876_u1) were purchased from Thermo Fisher
Scientific. For quantification of HIV-1 gag, primers and probe were purchased
from Thermo Fisher Scientific with the following sequences: forward, 5’ ACA
TCA AGC CAT GCA AAT-3’; reverse, 5’-ATC TGG CCT GGT GCA ATA GG-3’;
probe, 5’-FAM-CAT CAA TGA GGA AGC TGC AGA ATG GGA TAG A-TAMRA-
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3’. Real-time reverse-transcription polymerase chain reaction (RT-PCR) was
performed in a volume of 10 µl using the one-step quantitative TaqMan Realtime RT-PCR system (Applied Biosystems Inc.). For analysis of HIV-1 gag DNA,
real-time PCR was carried out directly on the DNA samples using the TaqMan
Universal Master Mix and a StepOne Plus Real-Time PCR System (Thermo
Fisher Scientific). Relative FOXO3a, TRAIL, CD4, CCR5 and HIV-1 gag levels
were determined and standardized with GAPDH or 18S rRNA internal control
using comparative ∆∆CT method. All primers used in the study were tested for
amplification efficiencies and the results were similar.
RANTES and MIP-1α ELISAs
Supernatants collected at 5 days post-infection were analyzed for RANTES
and MIP-1α levels by in-house ELISAs (paired antibodies, R&D Systems,
Minneapolis, MN) as previously described (101).
siRNA transfection
Predesigned siRNA duplexes targeting FOXO3a (ID: 144672) and a
negative control siRNA (catalog no. AM4611) were purchased from Thermo
Fisher Scientific. At 72 h after HIV-1 infection, cells were transfected with 100
nM siRNA duplexes for 4 h in DMEM culture medium without serum, in the
presence of siIMPORTER reagent (EMD Millipore Corporation, Billerica, MA)
according to the manufacturer’s instructions. At 72 h post-transfection, cells
were harvested and total RNA was extracted for the detection of FOXO3a and
TRAIL levels by real-time RT-PCR.
Statistical analysis
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Data are expressed as means ± SD unless otherwise specified. Statistical
analysis was performed by using one-way ANOVA, followed by the Tukey’spost-test for paired observations, or two-way ANOVA when two independent
variables are considered. The two-tailed Student’s t test was used to compare
two groups. Significance was determined by a p value < 0.05. All experiments
were performed with cells from at least three donors to account for any donorspecific differences. Assays were performed at least three times in triplicate or
quadruplicate within each assay.
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3.4 Results
ONC201 inactivates Akt and ERK in HIV-1 infected macrophages.
After showing the antiviral effect of ONC201 in vitro and in vivo, we
investigated the underlying mechanism of viral inhibition by focusing on the
FOXO3a-TRAIL pathway. In cancer cells, ONC201 inactivates two kinases, Akt
and ERK, to activate FOXO3a-TRAIL pathway (78). However, whether ONC201
targets the same kinases in HIV-1 infected macrophage is still unknown. To
answer this question, MDM were infected with HIV-1ADA for 24 hours and then
incubated with DMSO, ONC201 or its isomer for 5 days, which are the same
settings as the previous antiviral tests. First, we assessed the status of Akt in
HIV-1 infected MDM by measuring the levels of phosphorylated Akt, total Akt,
and β-actin though Western blots. After quantification, we found that the
phosphorylation of Akt, determined by the ratio of phosphorylated Akt over total
Akt, was decreased after ONC201 treatment in a dose-dependent manner
compared with treatment of isomer and DMSO controls (Fig. 3.1). Then we
assessed the status of ERK in the same cells and found a similar pattern that
phosphorylation of ERK decreased as ONC201 concentration increased (Fig.
3.2). These results indicate ONC201 inactivate both Akt and ERK in HIV-1
infected macrophages.
The antiviral effect of ONC201 in HIV-1 infected macrophages is dependent
on FOXO3a and TRAIL expressions.
To determine if the antiviral effect of ONC201 is mediated by FOXO3a,
knockdown of FOXO3a was performed by siRNA targeting FOXO3a in HIV-1-
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infected MDM. A non-targeting control siRNA was used as the control. We
assayed FOXO3a and TRAIL expression at 72 hours after siRNA transfection
and found that FOXO3a-targeting siRNA reduced the levels of FOXO3a and
TRAIL mRNA in HIV-1 infected macrophages (Fig. 3.3A and B), confirming that
FOXO3a has indeed been knocked down. In the control groups, ONC201
significantly decreased the HIV-1 replication levels, as measured by HIV-1
RTase activity assay, compared with those in the isomer treatment (Fig. 3.4).
However, FOXO3a knockdown reversed HIV-1 replication to the same level as
those in the isomer treated group, suggesting that FOXO3a knockdown blocks
the antiviral effect of ONC201 (Fig. 3.4).
To further determine if TRAIL also mediates the antiviral effect of ONC201,
we used 50 ng/ml or 100 ng/ml of the soluble TRAIL receptors to act as decoys
blocking activities of TRAIL on the surface of macrophages. In HIV-1 RTase
activity assay, we found that treatment of soluble TRAIL receptors reversed the
HIV-1 replication in ONC201-treated cells to the same level as those in the
isomer-treated group (Fig. 3.5A). Consistent with the RTase activity data,
treatment with soluble TRAIL receptors also significantly increased intracellular
HIV-1 p24 levels (Fig. 3.5B), suggesting that the antiviral effect of ONC201 in
HIV-1 infected macrophages is dependent on TRAIL expressions.
The antiviral effect of ONC201 in HIV-1 infected macrophages is associated
with apoptosis.
In cancer cells, activation of FOXO3a-TRAIL pathway by ONC201 leads to
cell apoptosis and death, while in HIV-1 infected MDM, treatment of human
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recombinant TRAIL induces cell apoptosis and death. Thus, we hypothesized
that ONC201 treatment should also induce cell apoptosis and death in HIV-1
infected macrophages. However, when MDM were first infected with HIV-1 and
then treated with ONC201 for 5 days, ONC201 treatment significantly increased
the cell viability (Fig. 3.6), possibly due to the significant decrease of HIV-1
replication at higher doses (3 - 30 μM) of ONC201 treatment. In other words,
ONC201 could have killed infected cells to protect the uninfected cells from
infection.
For better understanding the cytotoxic effect of ONC201 in HIV-1 infected
MDM, we pretreated MDM with ONC201 or its isomer for 5 days before 24-h
HIV-1 infection. ONC201 and isomer treatments continued during and after the
infection. At 3-day post infection, cell viability was determined by the MTS
assays. A significant and dose-dependent decrease of cell viability was
observed in ONC201-treated groups at the concentrations from 3 to 30 μM
compared with either isomer- or DMSO- treated groups (Fig. 3.7), showing that
pretreatment of ONC201 reduced the cell viability of HIV-1 infected MDM.
Enhanced level of caspase-3 cleavage is one of the indicators for cell apoptosis.
Western blots on caspase-3 showed that the cleavage of caspase-3, determined
by the ratio of cleaved caspase-3 over pro-caspase-3, was significantly
increased in a dose-dependent manner with ONC201 treatment (Fig. 3.8), which
is consistent with the results in cell viability assay. Meanwhile, analysis of HIV-1
replication by RTase activity assay showed that the ONC201 pretreatment
significantly lowered viral levels in the cell culture with a similar pattern to
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caspase-3 cleavage (Fig. 3.9). Together, we found that the antiviral effect of
ONC201 in HIV-1 infected macrophages is associated with apoptosis.
The antiviral effect of ONC201 in HIV-1 infected macrophages is associated
with autophagy.
In addition to apoptosis, autophagy as another target of FOXO3a-TRAIL
pathway also plays a role in restricting HIV-1 infection (135, 137, 142, 143). To
test whether ONC201 treatment induces autophagy in macrophages, we treated
both uninfected and HIV-1 infected MDM with various doses of ONC201 or its
isomer for 5 days. The levels of LC3 I, LC3 II and β-actin were measured by
Western blots to assess the status of autophagy. We found that in both
uninfected and HIV-1 infected MDM, the ratio of LC3 II to LC3 I as an indicator
for autophagy increased in a dose-dependent manner after ONC201 treatment
while the isomer treatment did not increase this ratio (Fig. 3.10 and 3.11). This
result indicates ONC201 induces autophagy in macrophage.
To further determine the role of autophagy in the antiviral effect of ONC201,
PI3K inhibitor 3-MA was used to block autophagy. HIV-1 infected MDM were
treated with either 3-MA, ONC201, or a combination of 3-MA and ONC201 for 5
days. Then the cell lysates were subjected to Western blots for the
measurement of p24, LC3 I, LC 3 II and β-actin (Fig. 3.12A). We found that
ONC201 treatment increased the LC3II/I ratio while cotreatment with 3-MA
reduced the ratio to the baseline, confirming that 3-MA inhibits the autophagy
induced by ONC201 (Fig. 3.12B). Meanwhile, ONC201 treatment decreased the
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P24 level whereas cotreatment with 3-MA removed this decrease (Fig. 3.12C).
Therefore, blocking autophagy by 3-MA reversed the antiviral effect of ONC201.
RANTES, MIP-1α, CD4 and CCR5 are not involved in the antiviral effect of
ONC201.
Because downstream targets of ONC201 include TRAIL, which belongs to
the TNF superfamily of cytokines, one plausible mechanism for HIV-1 inhibition
by ONC201 is through ONC201-induction of cytokines that interfere with the
HIV-1 lifecycle. RANTES (CCL5) and MIP-1α (CCL3) are both chemokines that
bind to CCR5, which function as a primary coreceptors for HIV-1 entry in MDM
cell (147, 148). We tested the RANTES and MIP-1α levels after ONC201
treatment and found that ONC201 did not increase the levels of these
chemokines in the supernatants (Fig. 3.13), suggesting that ONC201 is unlikely
to inhibit HIV-1 replication through inducing HIV-1 suppressive chemokines in
MDM.
To exclude other possible mechanisms that prohibit virus from entering the
macrophage, we also used quantitative real-time PCR to measure the levels of
HIV-1 coreceptors, CD4 and CCR5, in HIV-1 infected MDM with ONC201
treatment. The expression of both coreceptors did not change after ONC201
treatment (Fig. 3.14). Finally, ONC201 was not able to suppress HIV-1 when
directly incubated with HIV-1 virions (Fig. 3.15), suggesting that ONC201 may
not directly inactivate virus to protect cells from infection.
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3.5 Discussion
After demonstrating that ONC201 inhibits HIV-1 infection of reservoir cells
in vitro and in vivo, we further identified that the antiviral effect of ONC201 is
mediated by the FOXO3a/TRAIL pathway, as ONC201 activated FOXO3a and
induced TRAIL expression in HIV-1-infected macrophages, and knockdown of
FOXO3a or blocking TRAIL abrogated the antiviral activity of ONC201. The
antiviral effect of ONC201 is also associated with apoptosis and autophagy in
HIV-1 infected MDM, while direct inhibition or blocking viral entry is not the
mechanism underlying this effect.
Our studies identify that the antiviral effect of ONC201 in HIV-1 infected
macrophage is dependent on FOXO3a and TRAIL expressions. However, the
exact molecular interactions between ONC201 and FOXO3a remain to be
determined. Besides being a FOXO3a activator, ONC201 has also been
proposed as a selective dopamine receptor 2 (DRD2) antagonist (81, 149, 150).
DRD2

as

one

of

the

D2-class

dopamine

receptors

mediates

the

dephosphorylation of kinases Akt and ERK (151). However, previous studies
have shown ONC201 inactivates both Akt-1 and ERK1/2 to activate FOXO3a
and induce the transcription of TRAIL in cancer cell lines (78). We confirmed the
dual inactivation of Akt and ERK by ONC201 in HIV-1 infected macrophages.
The fact that ONC201 inactivates Akt and ERK is contrary to the expected
phosphorylation of these kinases by DRD2 antagonist, suggesting that ONC201
may have multiple targets other than DRD2 and the overall effect is the
inactivation of Akt and ERK. We observed that the phosphorylation of FOXO3a
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is decreased after ONC201 treatment in both uninfected and HIV-1 infected
MDM, indicating ONC201 targets the same signaling pathway in cancer cells.
Notably, it takes at least 3 days for FOXO3a to be fully activated by ONC201 (78,
79), which appears slow for direct kinase regulators, suggesting the activation of
FOXO3a is a late event following multi-level regulations triggered by ONC201.
Meanwhile, ONC201 is also known to “stresses tumor to death” by inducing
endoplasmic reticulum (ER) stress-related or integrated stress response (ISR)related genes, such as ATF4, CHOP, Growth arrest and DNA damage-inducible
protein GADD34, and Tribbles homolog 3 (TRIB3) (152). Whether these genes
work in tandem with FOXO3a/TRAIL pathway or not warrants future
investigations.
Having demonstrated that the antiviral effect of ONC201 relies on the
activation of FOXO3a/TRAIL pathway, we sought to elucidate the exact
mechanism by which activated TRAIL signaling reduces HIV-1 replication. One
potential mechanism is that TRAIL-mediated apoptosis clears the HIV-1 infected
reservoir cells. This is supported by previous reports demonstrating that leucinezipper TRAIL, agonistic anti-TRAIL receptor antibodies, and activated NK cellderived TRAIL induce apoptosis in MDM and peripheral blood lymphocytes and
consequently reduce viral burden in HIV-infected individuals (92, 153, 154). In
the HIV-1-infected macrophage culture with post-infection treatment of ONC201,
we were not able to pinpoint whether ONC201-mediated HIV suppression is
dependent upon the induction of apoptosis. The progress of HIV-1 infection in
the culture coincides with not only viral replication but also cell death and
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apoptosis. Therefore, if ONC201 inhibits HIV-1 replication by inducing apoptosis
in HIV-1-infected MDM, the viral inhibition could also work to negate the effect of
HIV-1-induced cell death, resulting in the absence of viability loss in the infected
MDM with post-infection treatment of ONC201 as seen in Fig. 3.6. To untangle
the possible mixed effects of ONC201 in HIV-1 infected MDM culture, we
changed the scheme of ONC201 treatment from post-infection treatment to
pretreatment. The short-term HIV-1 infection in this scheme minimizes the
interference of HIV-1-induced cell death with ONC201-induced cell death.
Pretreating MDM with ONC201 before HIV-1 infection lowered the cell viability
of HIV-1 infected MDM culture. An increased cleavage of caspase-3 and a
reduced level of HIV-1 infection parallel with this lowered cell viability, showing
the cell death induced by ONC201 is associated with cell apoptosis and the
latter might be responsible for the antiviral effect of ONC201. ONC201 did not
change the cell viability of uninfected MDM but reduce the cell viability of HIV-1
infected MDM after pretreatment, possibly due to the high expression of DR5 on
the membrane of HIV-1 infected MDM (62). Nevertheless, an apoptosisindependent mechanism could also seemingly explain the viability of HIV-1infected MDM upon ONC201 treatment. TRAIL signaling may change the status
of immune cells by interfering with the activation of NF-κB, PKB/Akt and MAPKs,
which are relevant factors for HIV-1 replication (155). Thus, more specific
experiments need to be developed to identify whether apoptosis is the main
mechanism for ONC201 and TRAIL effect in HIV-1-infected macrophages.
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Furthermore, TRAIL is also known to trigger autophagy in human
macrophage (143), which selectively degrades the HIV-1 Tat by p62/SQSTM1
(137) and causes preferential cell death of HIV-1-infected macrophages (156).
In our study, ONC201 treatment elevated the LC3 II/I ratio in both uninfected
and HIV-1 infected MDM and 3-MA treatment reversed the antiviral effect of
ONC201, suggesting autophagy might be involved in the antiviral effect of
ONC201. Nevertheless, these results need to be interpreted carefully
considering that autophagy is a complicated, multi-step process. In the late
phase of autophagy, LC3 II is degraded by lysosomal hydrolases considerably
and therefore can only serve as a marker for autophagosome in the early phage
of autophagy (157). PI3K inhibitor,3-MA, is usually considered to block
autophagy in the early phase (158). To further confirm the induction of
autophagy by ONC201 and pinpoint its specific role in the antiviral effect of
ONC201, more markers and blockers targeting the different phases of
autophagy will be needed.
Aside

from

FOXO3a-TRAIL

pathway,

other

possible

mechanisms

underlying the antiviral effect of ONC201 were also investigated. ONC201
decreases HIV-1 RTase activities in MDM through FOXO3a and TRAIL but likely
not through a direct inhibition of HIV-1 RTase activities since ONC201 is not
able to suppress HIV-1 when directly incubated with HIV-1 virions (Fig. 3.15).
No change in the expression levels of RANTES, MIP-1α, CD4 and CCR5 were
observed after ONC201 treatment, suggesting that ONC201 did not change the

85
status of HIV-1 receptors on the surface of macrophages to prevent the entry of
viruses.
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3.6 Figures
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Figure 3.1 ONC201 inactivates Akt in HIV-1 infected macrophages.
Human MDM were plated in 24-well plates in triplicate and then infected with
HIV-1ADA for 1 day. The cells were incubated with doses of ONC201 or ONC201
isomer ranging from 3 to 30 μM for 5 days. Cells were then harvested and cell
lysates were subjected to SDS-PAGE and immunoblotting for the phospho-AKT
or total AKT. Actin was used as the loading control. Densitometric
quantifications of phospho-AKT in MDM were presented as a ratio to total AKT
and normalized as fold changes to the no treatment control. Values represent
SEM of biological replicates. ANOVA analysis: ** denotes p < 0.01, compared to
DMSO group; ## denotes p < 0.01, compared to the ONC201 treatment group
with the same concentration.
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Figure 3.2 ONC201 inactivates ERK in HIV-1 infected macrophages.
Human MDM were plated in 24-well plates in triplicate and then infected with
HIV-1ADA for 1 day. The cells were incubated with doses of ONC201 or ONC201
isomer ranging from 3 to 30 μM for 5 days. Cells were then harvested and cell
lysates were subjected to SDS-PAGE and immunoblotting for the phospho-ERK
or total ERK. Actin was used as the loading control. Densitometric
quantifications of phospho-ERK in MDM were presented as a ratio to total ERK
and normalized as fold changes to the no treatment control. Values represent
SEM of biological replicates. ANOVA analysis: ** denotes p < 0.01, compared to
DMSO group; ## denotes p < 0.01, compared to ONC201 treatment group with
the same concentration.
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Figure 3.3 Knockdown of FOXO3a reduces the expression of FOXO3a
and TRAIL. Human MDM were plated in 24-well plates and then infected with
HIV-1ADA for 24 hours before incubation with ONC201 or ONC201 isomer at 30
μM for 5 days. At 2 days post HIV-1 infection, MDM were transfected with either
non-targeting control siRNA or FOXO3a siRNA. At the experimental end point,
FOXO3a and TRAIL mRNA were detected in total cellular RNA through real
time RT-PCR. Data were normalized to 18S rRNA and presented as fold change
compared to control siRNA group with isomer treatment. Values represent SEM
of biological replicates. ANOVA analysis: ## denotes p < 0.01, compared with
the control siRNA group with ONC201 treatment; ### denotes p < 0.001,
compared with the control siRNA group with ONC201 treatment.
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Figure 3.4 Antiviral effect of ONC201 is dependent upon FOXO3a in
HIV-1-infected macrophages. Human MDM were plated in 24-well plates and
then infected with HIV-1ADA for 24 hours before incubation with ONC201 or
ONC201 isomer at 30 μM for 5 days. At 2 days post HIV-1 infection, MDM were
transfected with either non-targeting control siRNA or FOXO3a siRNA. HIV-1
infection levels were determined by the RTase activity assay. Values represent
SEM of biological replicates. ANOVA analysis: *** denotes p < 0.001, compared
with the control siRNA group with isomer treatment; ### denotes p < 0.001,
compared with the control siRNA group with ONC201 treatment.
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Figure 3.5 Antiviral effect of ONC201 in HIV-1 infected macrophage is
dependent on TRAIL expression. HIV-1-infected MDM were incubated with
ONC201 or ONC201 isomer at 30 μM, along with 100ng/ml, 50ng/ml soluble
TRAIL receptor, or 100ng/ml soluble TNF receptor as control for 5 days. A) HIV1 infection levels were determined by RTase activity assay. B) Cell lysates were
subjected to SDS-PAGE and immunoblotting for HIV-1 p24. Actin was used as
the loading control. Densitometric quantifications of p24 in MDM were presented
as a ratio to actin and normalized as fold changes to the control group. ANOVA
analysis: *** denotes p < 0.001, compared with the control group with isomer
treatment; ### denotes p < 0.001, compared the control group with ONC201
treatment.
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Figure 3.6 Post-infection treatment of ONC201 does not reduce the cell
viability of HIV-1 infected macrophage culture. Human MDM were plated in
96-well plates and infected with HIV-1 for 24 hours before incubation with doses
of ONC201 or its isomer ranging from 0.03 to 30 μM. At 5-day post ONC201 and
isomer treatments, cell viability was determined by the MTS assays. Results
shown are from representative experiments performed with three different
donors. Data were analyzed by two-way ANOVA: * denotes p < 0.05, ** denotes
p < 0.01 and *** denotes p < 0.001.
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Figure 3.7 Pretreatment of ONC201 reduces the cell viability of HIV-1
infected macrophage culture. Human MDM were plated in 96-well plates and
incubated with doses of ONC201 or its isomer ranging from 3 to 30 μM for 5
days before infection with HIV-1 for 24 hours. ONC201 and isomer treatments
continued during and after the infection. At 3-day post infection, cell viability was
determined by the MTS assays. Results shown are from representative
experiments performed with three different donors. Data were analyzed by twoway ANOVA: * denotes p < 0.05, ** denotes p < 0.01 and *** denotes p < 0.001.
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Figure 3.8 Pretreatment of ONC201 induces cleavage of caspase-3 in
HIV-1 infected macrophage. Human MDM were plated in 96-well plates and
incubated with doses of ONC201 or its isomer ranging from 3 to 30 μM for 5
days before infection with HIV-1 for 24 hours. ONC201 and isomer treatments
continued during and after the infection. A) At 3-day post infection, cell lysates
were collected and subsequently subjected to SDS-PAGE and immunoblotting
for the detection of cleaved caspase-3 and pro-caspase-3. Actin was used as
the loading control. B) Densitometric quantifications of cleaved caspase-3 in
MDM were presented as a ratio to total caspase-3 and normalized as fold
changes to the no treatment control. Values represent SEM of biological
replicates. ANOVA analysis: * denotes p <0.05 and ** denotes p < 0.01,
compared with the DMSO group.
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Figure 3.9 Pretreatment of ONC201 on macrophages inhibits HIV-1
infection. Human MDM were plated in 96-well plates and incubated with doses
of ONC201 or its isomer ranging from 3 to 30 μM for 5 days before infection with
HIV-1 for 24 hours. ONC201 and isomer treatments continued during and after
the infection. At 3-day post infection, supernatants were removed and the
replication levels of HIV-1 were monitored by RTase activity assay. Results
shown are from representative experiments performed with three different
donors. Data were analyzed by two-way ANOVA: * denotes p < 0.05, ** denotes
p < 0.01 and *** denotes p < 0.001.
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Figure 3.10 ONC201 induces autophagy in uninfected macrophages.
Human MDM were plated in 24-well plates and then incubated with ONC201 or
ONC201 isomer at 3 to 30 μM for 5 days. Cell lysates were collected and
subsequently subjected to SDS-PAGE and immunoblotting for the detection of
LC3 I and LC3 II. Actin was used as the loading control. Densitometric
quantifications of LC3 II in MDM were presented as a ratio to LC3 I and
normalized as fold changes to the no treatment control.
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Figure

3.11

ONC201

induces

autophagy

in

HIV-1

infected

macrophages. Human MDM were plated in 24-well plates and then infected
with HIV-1ADA for 24 hours before incubation with ONC201 or ONC201 isomer at
3 to 30 μM for 5 days. Cell lysates were collected and subsequently subjected to
SDS-PAGE and immunoblotting for the detection of LC3 II and LC3 I. Actin was
used as the loading control. Densitometric quantifications of LC3 II in MDM were
presented as a ratio to LC3 I and normalized as fold changes to the no
treatment control.
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Figure 3.12 Blocking autophagy by 3-MA reverses the antiviral effect
of ONC201. Human MDM were plated in 24-well plates and then infected with
HIV-1ADA for 24 hours before incubation with ONC201 (30 μM), 3-MA (100 μM)
or a combination of ONC201 and 3-MA for 5 days. A) Cell lysates were collected
and subsequently subjected to SDS-PAGE and immunoblotting for the detection
of LC3 II, LC3 I and P24. Actin was used as the loading control. B)
Densitometric quantifications of LC3 II in MDM were presented as a ratio to LC3
I and normalized as fold changes to the DMSO control. C) Densitometric
quantifications of P24 in MDM were presented as a ratio to actin and normalized
as fold changes to the control group. ANOVA analysis: * denotes p < 0.05,
compared to DMSO group; # denotes p < 0.05, compared to ONC201 treatment
group.
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Figure 3.13 ONC201 does not induce the production of RANTES and
MIP-1α. Human MDM were plated in 24-well plates in triplicate and then
infected with HIV-1ADA for 24 hours before incubation with ONC201 or ONC201
isomer at 30 μM for 5 days. RANTES and MIP-1α concentration (ng/ml) was
determined from cell culture supernatants using ELISA and adjusted to
intracellular protein concentrations. Values represent SEM of biological
replicates. ANOVA analysis: * denotes p <0.05 compared with DMSO group; #
denotes p < 0.05 compared with ONC201 treatment group.
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Figure 3.14 ONC201 does not change the expression of CCR5 and CD4
in HIV-1 infected macrophages. Human MDM were plated in 24-well plates in
triplicate and then infected with HIV-1ADA for 1 day. The cells were incubated
with doses of ONC201 or ONC201 isomer ranging from 3 to 30 μM for 5 days.
Cells were then harvested and RNA was isolated. CCR5 and CD4 expression
were determined through quantitative real time RT-PCR. Relative CCR5 and
CD4 expression levels were determined and standardized with GAPDH internal
control. Values represent SEM of biological replicates. ANOVA analysis: **
denotes p < 0.01, compared to DMSO group.
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Figure 3.15 ONC201 does not suppress HIV-1 when directly incubated
with HIV-1 virions. Equal viral titers (400 TCID50/ml) of laboratory-adapted HIV
strain ADA were mixed with doses of ONC201 ranging from 0.1 to 30 μM. The
reverse transcriptase activity of HIV-1 was monitored by RTase activity assay.
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4.1 General discussion
Even in the early phase of infection, HIV enters the CNS and evades
ART(159). These viruses incur chronic inflammation and tissue damage that
causes the development of complications such as HAND in more than half of
infected patients(160). In the post-ART era, the complications are even more
prevailing for the long life expectancy of infected patients on ART and poor BBB
penetration of ART drugs (161, 162). HIV-1 infected macrophages and microglia,
as the reservoir cells in CNS, play a central role in the development of
HAND(144). This study targets the long-lived nature of the macrophages and
microglia and use the latest understanding of their vulnerabilities to design new
therapies for viral eradication. We intended to introduce ONC201, an effective
apoptosis-inducing agent in cancer biology, to the HIV field for eradicating
infected macrophages and microglia. We observed the antiviral effect of
ONC201 on HIV-1 infected macrophages both in vitro and in vivo, and
elucidated that the activation of FOXO3a-TRAIL pathway is the main
mechanism underlying this antiviral effect.
This study is innovative in three aspects. First, this study makes a
conceptual advance in understanding the molecular mechanism of HIV-1
persistence in the CNS. Targeting transcription factors for therapeutic aims is a
largely unexplored area. In the current study we uniquely investigated a
transcription factor FOXO3a in its crucial contribution to the HIV-1 persistence in
the CNS. It provides an important proof-of-concept that endogenous FOXO3a
could be harnessed to combat persistent and latent HIV-1 infection. This new
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strategy to change the balance of pro- and anti-apoptotic factors in infected cells
will stimulate further development of therapeutic strategies to eradicate viral
reservoirs. Second, this study takes advantage of the latest drug development
on FOXO3a (78). The novel drug has the potential to eliminate HIV-1-infected
cells in the CNS and significantly increase the efficacy of ART. Third, this study
is innovative in using the technology of HIV-1 encephalitis (HIVE) mouse model.
The HIVE mouse model is suitable to study the survival of long-lived HIV-1
infected cells and the effect of TIC10-induced pro-apoptotic genes upregulation.
The data from this pilot study on HIVE mouse model are the first evidence of
FOXO3a involvement in survival of infected cells in vivo.
The physiological relevance of pharmacological intervention on TRAIL
expression is significant. In HIV-1 infected patients, both soluble TRAIL in their
serum and surface-bound TRAIL on the membrane of their cells are upregulated
(64, 93). However, the elevated level of TRAIL is not sufficient to clear the
infected reservoir cells. This could be attributed to the TRAIL resistance
conferred from TRAILshort. TRAILshort is a novel splice variant of TRAIL that
lacks apoptosis-inducing activity and acts as an antagonist of TRAIL (122, 163).
This antagonism is further strengthened by its preference of binding to death
receptors, TRAIL-R1 and -R2, rather than decoy receptors, TRAIL-R3 and R4(122). TRAILshort is produced by both HIV-1 infected cells and uninfected
bystander cells, and its production is induced by type I IFNs and TLR7, TLR8,
and TLR9 agonists(122). Furthermore, it can be wrapped into microvesicles and
then brought to neighboring cells, which establishes a TRAIL-resistant
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microenvironment(122). However, supraphysiologic levels of TRAIL agonists
and TRAIL-inducer ONC201 are still able to preferentially kill these HIV-1
infected cells(62), suggesting this TRAIL-resistant microenvironment could be
overcome by higher levels of TRAIL. Development of more potent TRAIL
agonists or TRAIL-inducers are warranted.
Compared with other currently available TRAIL-based drugs, TRAIL as a
small molecule shows advantages. Recombinant TRAIL, adenovirus-delivered
TRAIL

and

longer-lived

TRAIL

receptor

agonist

antibodies

such

as

lexatumumab and mapatumumab have been tested in clinical trials and showed
antitumor effects (112-118, 164). However, synthesis of these macromolecules
is costly, their biodistribution is limited and their half-life is relatively short.
ONC201 performs better in bioavailability, biodistribution, stability and cost(79).
In addition, the most attractive trait of ONC201 is that it can induce endogenous
production of TRAIL not only by the target cells but also by the neighboring cells.
It means all the uninfected cells in human body are potentially able to produce
and secrete soluble TRAIL that may induce apoptosis of HIV-1 infected cells.
Cells can also produce surface-bound TRAIL that kills the infected nearby cells
through a bystander effect. Thus, inducing endogenous TRAIL production by a
small

molecule

is

much

more

effective

than

providing

exogenous

macromolecules. This also suggests that ONC201 may have a better antiviral
effect in a mixed glia cell culture or in the in vivo models than in the current
MDM-only culture.
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In this study, we proposed that ONC201 inhibits HIV-1 infection through
TRAIL-induced apoptosis, which belongs to “prime, shock and kill” strategy of
managing latently infected cells. This is further supported by the following facts:
1) HIV-1 infection inhibits Akt-1 phosphorylation (66); 2) FOXO3a- and TRAILmediated apoptosis in HIV-1 infected macrophages is dependent on the
inhibition of Akt-1 phosphorylation (41, 66); 3) ONC201 activates FOXO3aTRAIL pathway via inhibition of Akt-1 phosphorylation(78). Together, ONC201
may inhibit Akt-1 to induce apoptosis in HIV-1 infected macrophages, which
seems to be the mechanism for the antiviral effect of ONC201. However, latest
evidence shows that Akt activation is critical for HIV-1 reactivation in latently
infected cell line and ART drugs limits this viral reactivation by inhibiting
Akt(125). This suggests that ONC201 as an Akt inhibitor may reduce the size of
the HIV reservoir through a “block and lock” strategy, which is opposite to our
original hypothesis. It is also possible that the antiviral effect of ONC201 on HIV1 infected reservoir cells is through both “prime, shock and kill” and “block and
lock” strategies. If so, this two-fold effect would make ONC201 more appealing
for the future clinical application.
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4.2 Future directions
The United States is currently experiencing a grave epidemic of drug abuse
such as psychostimulants involving cocaine and methamphetamine, particularly
among patients infected with HIV (165). Drug abuse and HIV infection frequently
coexist due to the association of drug use with engagement of high-risk
behaviors (166). More importantly, drug abuse has been correlated with severe
HAND and more rapid progression to AIDS in HIV-infected people (167, 168).
Nevertheless, how drug abuse enhances HIV-related neuropathologies are not
fully understood. Central to the action of drugs of abuse is dopamine, since
psychostimulants such as cocaine and methamphetamine all exert addictive and
reinforcing effects through elevation of extracellular dopamine levels in the CNS
(144). Thus, macrophages and microglia in CNS are exposed to high level of
dopamine for the drug abuser. Previous study has shown that exposure to
dopamine during infection increased the entry of R5 tropic HIV into
macrophages (146), suggesting that dopamine pathway could be a therapeutic
target for delaying or preventing the acceleration of HAND and other HIV-related
pathologies enhanced by drug abuse.
Dopamine signals primarily through dopamine receptors (DR), members of
the G protein coupled receptor superfamily. DR can be divided into two
subclasses, the D1-like DR, DRD1 and DRD5, and the D2-like DR, DRD2,
DRD3 and DRD4. Human monocyte-derived macrophages express mRNA for
all DR subtypes and protein for DRD1, DRD2, DRD3 and DRD4 in the plasma
membrane (144, 145). It has been reported that dopamine increases HIV
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replication in human macrophages by activation of DRD2 and increasing ERK 1
phosphorylation (144).
Specific DRD2 antagonist has been lacking. ONC201 was newly found to
selectively antagonize the DRD2, but not D1-like subfamily of dopamine
receptors (149). ONC201 shows superior traits among current DRD2
antagonists. In addition to high selectivity, ONC201 exhibited a very slow
association rate for DRD2 relative to antipsychotics, whereas the dissociation
rate was similar to atypical antipsychotics that are better tolerated clinically
(unpublished). However, no groups have introduced this drug into HIV field as a
DRD2 antagonist for treating HIV-related neurological disorders among infected
drug abusers. We have demonstrated that ONC201 reduces HIV-1 replication in
human macrophages and microglia both in in vitro primary cultures and in vivo
murine HIV encephalitis model. However, whether blocking DRD2 by ONC201
could halt HIV-1/drug abuses co-morbidities remains unclear.
We will first determine whether the antiviral effect of ONC201 in
macrophages is through antagonizing DRD2. DRD2-selective agonist quinpirole
will be used together with ONC201 on HIV-1 infected macrophage to test
whether the DRDR agonist could abrogate the antiviral effect of ONC201. Then
we will use two different siRNAs for DRD2 to lower the expression of DRD2 in
MDM two days before HIV-1 infection, to see whether knockdown of DRD2
would be sufficient to suppress the HIV-1 infection in macrophage. We will also
use HIVBaL containing Vpr-b-lactamase and phenol red free macrophage media
with CCF2-AM to perform viral entry assay, to determine whether this DRD2-
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mediated antiviral effect of ONC201 is through blocking the entry of HIV into
cells. In this assay, uninfected cells fluoresce green and infected cells fluoresce
blue.
Evaluating the in vivo therapeutic potential of ONC201 is the most
significant part of our study and a natural progression of the in vitro studies. We
have used a murine HIV encephalitis (HIVE) model to show the antiviral effect of
ONC201 on the HIV-1 infection levels in the brain. Nevertheless, the humanized
mice model is more suitable to examine multiple parameters of HIV-1
pathogenesis including eradication of infected macrophages and latently
infected T cells as viral reservoir. We will further use the CD34 engrafted model
of neuroAIDS to examine whether ONC201 affects multiple parameters of HIV-1
pathogenesis, including persistence of infected macrophages and latently
infected T cells as viral reservoir. This first proof-of-principle data will usher in an
innovative therapy that targets FOXO3a for viral eradication.
Using CD34-engrafted humanized mouse model of neuroAIDS, we will test
whether ONC201 and the standard ART can synergistically reduce the CNS
viral load and delay viral rebound. Meanwhile, we will identify whether ONC201
is able to suppress viral replication in the HIV-1-infected humanized mice
through induction of TRAIL. After 15 weeks of reconstitution by human CD34+
stem cells, humanized NSG mice will be selected for further study based on
their repopulation with human CD45+ cell numbers as monitored in peripheral
blood. These animals will be infected with the macrophage tropic virus HIV-1ADA
by IP injection and randomized into 9 groups, 8 of which are all HIV-1 infected
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animal groups. Four of the groups will receive ART, whereas the other groups
serve as control. For ART, HIV-infected mice will be treated by daily injection of
ART drugs for 3 weeks. For Non-ART group, mice will be daily-administered
ONC201, DMSO/IgG vehicle control, TRAIL neutralizing antibody, or ONC201+
TRAIL neutralizing antibody through IP. At the end point of 3 weeks post HIV-1
infection, whole brain tissues will be collected for DNA/RNA isolation and IHC.
For the 4 ART groups, mice will be daily-administrated ONC201, DMSO/IgG
vehicle control, TRAIL neutralizing antibody, or ONC201+ TRAIL neutralizing
antibody through IP along with ART. At 3 weeks post HIV-1 inoculation, all ART
will discontinue, facilitating viral rebound. All 4 groups will be followed for
another two weeks to the experimental point. Whole brain tissues will be
collected for DNA/RNA isolation and IHC. A ninth group of humanized NSG
mice will be uninfected and untreated, serving as negative controls (HIV−).
In addition to whole brain tissues, spleen, brain, liver, lymph nodes and
plasma will be also collected for drug levels and antiviral activity determination.
Specifically, FACS tests and ELISA of peripheral blood will be performed at
three different time points after infection to monitor the counts of CD4 + T-cells
and plasma viral load in HIV-1 infected mice. Immunohistochemistry or RNA In
Situ Hybridization (RNA ISH) on spleen, brain and lymph nodes will be
performed by staining for CD3, CD68 and HIV-1p24 or hybridizing HIV-1 RNA to
confirm the viral load tests. Pharmacokinetic analyses will be performed in
spleen, brain, and liver to measure the drug levels of ONC201 in such sites.
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Lastly, we will evaluate the cognitive function of the humanized mice through
fear conditioning tests the day before sacrifice.
One limitation of the humanized mouse models is that microglia within the
brain parenchyma are not humanized and could not be infected. Therefore, the
models could not fully recapitulate HIV-1 infection in these cell types. In
humanized mice, only peripheral monocytes and macrophages and CD4+ T
lymphocytes migrating across the BBB are infected and that infection is limited
to the meninges and perivascular spaces (169, 170). Although the current
models are suitable for testing ONC201 in vivo, this limitation reminds us that
continued improvement of animal model for HIV-1 infection is imperative.
As the growing epidemics of drug abuse and HIV become even more
interconnected, it has become increasingly important to understand the
influence of drugs of abuse in concert with HIV on the development of HAND
and intervene with this pathogenesis. The proposed studies will provide
important proof-of-concept that DRD2 on macrophages and microglia could be a
potential target for multiple drugs of abuse. Understanding the effect of ONC201
on HIV-1-infected macrophages and microglia in drug abuse and its underlying
mechanism will reveal new insights for delaying or preventing the acceleration of
HAND and other HIV-related pathologies enhanced by drug abuse.
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